Spenser Lin No Comments

Event Recap – August 26th, 2026

AI is becoming a real value-creation tool in healthcare.

Great panel and networking event this week exploring “AI Secrets: How Healthcare Owners Can Maximize Efficiency & Valuations.” We heard practical examples of how owners and providers are using AI to improve operations, drive EBITDA and build more valuable businesses ahead of a raise or exit.

AI is moving from buzzword to real value creation in healthcare.

Great discussion at our AI Secrets: How Healthcare Owners Can Maximize Tools for Efficiency & Higher Valuations event, bringing together healthcare business owners, investors and industry experts to share what’s actually working.

We explored practical ways healthcare companies are using AI to improve efficiency, reduce costs, strengthen operations and ultimately maximize value ahead of an exit.

Thank you to our outstanding panelists:
• Kathleen Van Schaik — Porter Wright Morris & Arthur LLP
• Tim Raderstorf — Steadywell
• BJ Yurkovich — Elevate CFO
• Neil Johnson — Lawrence, Evans & Co. (Moderator)

And a special thank you to Porter Wright Morris & Arthur LLP and for sponsoring and helping make the event possible.

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 31st, 2026

LECO_Weekly-Healthcare-News_8-31-2026Download

Healthcare Weekly News and Deals

  1. Sword Health to acquire OrangeDot, the parent company of Headspace, in an all-cash transaction reported between $200-$300 million. Sword Health, last valued at about $4 billion after raising just under $500 million, is buying OrangeDot for cash, with OrangeDot surviving as a wholly owned subsidiary. The $200–300 million range is a severe markdown against the roughly $3 billion at which Headspace and Ginger combined in 2021 and sits below the $321 million Headspace had raised. The deal follows Sword’s $285 million purchase of Kaia Health and extends its move from musculoskeletal care into behavioural health alongside its Mind and Dawn products. The Massachusetts filing dates from 22 July; the effective date is 14 September. (Link)
  2. American Healthcare REIT, Inc. (NYSE: AHR) has completed a $197 million acquisition of two Northern California senior housing communities from a joint venture between Affinius Capital and Alliance Residential Co. American Healthcare REIT has bought Sonrisa Senior Living in Roseville, rebranded Avella at Roseville, and The Watermark at Almaden, 545 units in total, for $197 million. Sonrisa alone traded at $94.1 million. The buyer has now completed roughly $1.4 billion of senior living acquisitions in 2026 and is pursuing a pipeline including $953 million under executed agreements, among them an $873 million Kensington portfolio. Senior housing occupancy reached 89.9% in the second quarter. Note the source headline wrongly casts the REIT as seller. (Link)
  3. Thomas Park Investments has acquired a four-property, $70 million medical outpatient portfolio from Stewart Investment Properties. The Annapolis healthcare real estate platform paid $70 million for 165,637 square feet across three Mid-Atlantic submarkets. The package is 1420 Beverly Road in McLean, a 47,185-square-foot building fully leased and anchored by MedStar Health; 6849 Old Dominion Drive in McLean, 69,330 square feet and 89% leased with Johns Hopkins Medicine as anchor; Children’s National at the former Takoma Theatre on Fourth Street NW in Washington, 24,140 square feet; and Luminis Health Easton Pavilion in Easton, Maryland, 24,982 square feet and fully leased to Luminis Health. Each asset is health-system anchored with remaining term and contractual rent growth. (Link)
  4. Ambulatory Partner Holdings has agreed to pay $54 million for a 60% stake in Atlas Surgery Center, the physician-owned neurosurgical ASC in Amherst, New York. Ambulatory Partner Holdings, an LLC owned equally by Rafael Axen, M.D., Matthew Jenkins and Ann Sariego, is buying 60% from seven of the nine physician members who together hold 90%.. Atlas, at 50 George Karl Boulevard, is a multispecialty Article 28 centre known for outpatient neurosurgery, angiograms, carotid stenting and complex spine, running on the order of 3,000 cases a year. Purchase price is equity-funded. New York’s Public Health and Health Planning Council has the establishment application on its 17 September agenda. (Link)
  5. The Federal Trade Commission has approved the final consent order clearing Ascension Health Alliance’s $3.9 billion acquisition of AmSurg LLC. The FTC finalised its order on 25 August, letting Ascension close a $3.9 billion purchase first agreed in mid-2025. Six centres go to SC Affiliates, a national ASC operator, and a seventh in Panama City to Florida Gastroenterology Center, a physician group already holding a minority stake. The divestitures cover Nashville, Panama City, Tulsa, Waco and Wichita, where the agency alleged reduced competition in gastroenterology, ophthalmology and orthopaedic outpatient procedures. Ascension must also give the FTC prior notice of ASC acquisitions in those metros for ten years. AmSurg operates more than 250 centres across 34 states. (Link)
  6. McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC from Blackstone (NYSE: BX) for approximately $2.25 billion. McKesson is paying roughly $2.25 billion for the Bethesda-based business after a multi-year Blackstone hold. The buyer is underwriting a services asset rather than a distribution one: biomarker intelligence, laboratory services, a global CRO, market access consulting and commercialisation support. That fits a portfolio McKesson has been reshaping by shedding non-core assets and concentrating capital in oncology and specialty, where Oncology & Multispecialty revenue rose 33% to $14.2 billion in fiscal first quarter 2026. The target will report inside that segment. Closing is subject to customary conditions and regulatory clearances. (Link)
  7. Eli Lilly and Company (NYSE: LLY) to acquire Merida Biosciences for up to $2.875 billion in cash, adding a precision immunology platform aimed at pathogenic autoantibodies. Consideration is cash up to $2.875 billion, covering an undisclosed upfront payment and contingent milestones. Cambridge-based Merida is building biologics that selectively degrade disease-causing antibodies while sparing normal immune function. Lead program MER511 is in Phase 1 for Graves’ disease and thyroid eye disease, with initial data showing reductions in pathogenic thyroid-stimulating antibodies and a favourable safety profile. A preclinical program, MER769, targets food allergy, asthma and chronic spontaneous urticaria. Merida launched last year with a $121 million Series A co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures. Close is expected in the fourth quarter, subject to customary clearances. (Link)
  8. Argenx SE (Euronext & Nasdaq: ARGX) completed a $2.2 billion all-cash acquisition of Forte Biosciences, Inc. (Nasdaq: FBRX) at $77.00 per share. The close, announced 27 August, follows a cash tender that drew about 87% of Forte shares. The deal adds FB102, which has clinical proof-of-concept in vitiligo and celiac disease and potential application across multiple autoimmune indications, to argenx’s immunology portfolio. The original agreement was signed 27 July at a 40.5% premium to Forte’s then-close. The transaction extends a 2026 pattern of large-cap immunology buyers paying for de-risked, mechanism-differentiated assets rather than waiting for later-stage readouts. Forte is now a wholly owned subsidiary and will delist from Nasdaq. (Link)
  9. Advent International has signed a definitive agreement to acquire a majority stake in New Zealand Clinical Research Group in a transaction local press valued at roughly NZ$1 billion, with Waterman Capital and clinician shareholders rolling over. Advent, one of the largest global private equity firms, is buying majority control of NZCR Group, a physician-led clinical trials platform operating across New Zealand and Australia under the NZCR, CMAX, Optimal and Fusion brands. Advent’s own release did not print a price; BusinessDesk and the Australian Financial Review put the equity value at about NZ$1 billion. Waterman Capital, which held 52%, and clinician shareholders are keeping a significant minority. Close is targeted for the fourth quarter subject to regulatory approvals. Advent will partner with CEO Tony Moffatt to deepen sponsor relationships and extend the network internationally. (Link)
  10. Radiology Partners has signed a definitive agreement to acquire Everlight Radiology from UK private equity firm Livingbridge in a cross-border teleradiology transaction reported at roughly $1 billion (approximately A$1 billion, or about US$715 million). Livingbridge is exiting Everlight after taking majority control in 2021 for a reported US$344 million, having itself bought the asset from Intermediate Capital Group. Everlight’s 800-plus consultant radiologists across 40-plus countries read on a follow-the-sun basis, roughly 2.5 million exams a year for 340-plus clients, avoiding premium US night-shift rates. Radiology Partners intends to extend Mosaic Drafting AI across the acquired network. The 17 August edition covered Livingbridge putting the asset up for sale with Radiology Partners named as bidder; this is the signed agreement. Regulatory clearances pending. (Link)
  11. TowerBrook Capital Partners to acquire a majority stake in Korean-American women’s wellness brand Rael for 400 billion won ($290 million), buying out a shareholder register including SoftBank Ventures, Unilever Ventures, Lotte Shopping, Shinsegae and GS Retail. TowerBrook is paying 400 billion won, about $290 million, for majority control of Rael, according to people familiar with the matter. The sponsor is buying a consumer health asset with a proven digital channel: Rael became Amazon’s top-selling sanitary pad label on an organic feminine care proposition. The cap table it is taking out is unusually broad for a brand of this size, spanning venture investors SoftBank Ventures and Unilever Ventures alongside strategic Korean retail capital from Lotte Shopping, Shinsegae and GS Retail. The deal is a rare cross-border consumer exit for Korean sponsors in a market skewed toward beauty. (Link)
  12. BioXcel Therapeutics, Inc. (Nasdaq: BTAI) has filed Chapter 11 and entered a stalking-horse sale with Teva Pharmaceuticals at $57.5 million upfront with milestones up to $125 million. BioXcel and two OnkosXcel subsidiaries petitioned in Delaware on 27 August to run a court-supervised 363 sale of substantially all assets. Teva Pharmaceuticals International GmbH is the stalking-horse bidder for $57.5 million in cash, assumption of specified liabilities, and up to $67.5 million of contingent development payments — a ceiling of $125 million if milestones hit. The estate includes IGALMI, the approved dexmedetomidine sublingual film for agitation, and the pending BXCL501 at-home filing. Teva posted a $5.7 million good-faith deposit and framed the bid as consistent with its Pivot to Growth business-development screen. Higher bids can still emerge at auction. (Link)
  13. Beyond Air, Inc. (Nasdaq: XAIR) has agreed to sell its controlling stake in NeuroNOS Israel Ltd. to Tel Aviv-listed UNIVO Pharmaceutical Industries (TASE: UNVO) for equity, warrants and up to $32.5 million in milestones. Beyond Air is selling 5,000,000 ordinary shares, about 58% of NeuroNOS on a fully diluted basis. Consideration is UNIVO ordinary shares equal to 19.99% of UNIVO’s issued capital, five-year warrants on a further 19.99% of UNIVO awards exercisable at $0.01, plus up to $6.5 million in cash development milestones and up to $26 million in commercial milestones. NeuroNOS is developing blood-brain-barrier-crossing small molecules that regulate nitric oxide, including BA-102 for autism spectrum disorder and Alzheimer’s and BA-101 for glioblastoma, both still preclinical. The sale lets Beyond Air concentrate on its nitric-oxide device franchise. (Link)
  14. Savista, the Alpharetta-based healthcare operations and revenue cycle management company, has acquired ABW Medical, an ambulatory revenue cycle management provider serving federally qualified health centres, medical groups, MSOs and virtual care platforms. Savista is buying its way out of a single-segment concentration. Its existing base is acute: more than 800 clients across 49 states, an Epic-certified training workforce and cancer registry services built over 35 years. ABW Medical adds the non-acute end, including community health centres, FQHCs, rural providers and virtual care, plus preferred RCM partner status inside the athenahealth ecosystem. That diversifies EMR exposure away from Epic dependence and adds safety-net billing around Medicaid wraparound payments. Clients pick up Savista’s global delivery scale and eligibility, coding and A/R tooling. (Link)
  15. Eqwal Group has acquired Atlantic Pro Care, the Portland, Maine prosthetics and orthotics practice, extending the French patient-care network’s East Coast footprint. Eqwal is a global prosthetics and orthotics patient-care group that already owns Steeper in the UK and has been rolling up US clinics including United Prosthetics, American Orthopedics, Optech, South Beach Prosthetics and Prosthetic & Orthotic Group. Atlantic Pro Care, founded in 1993 by J.P. Donovan in Portland, fits custom devices for patients with upper- and lower-limb loss and spinal conditions and handles assessment, fabrication, fitting and rehab. The buyer framed the tuck-in as deepening US patient-care density rather than adding a product brand. No purchase price was published. (Link)
  16. Thurston Group, the Chicago healthcare-focused private equity firm, has made a platform investment in Pixel Health, a Holyoke, Massachusetts provider of IT consulting and managed services to hospitals and large physician groups. Thurston is entering healthcare IT services for the first time through Pixel Health, founded in 2001 and built into a multi-brand group spanning strategy and transformation consulting, managed IT services, and product sales and licensing. Managing partner Dan Davis framed the deal as consistent with the firm’s practice of backing leaders in high-growth healthcare verticals. The sponsor has installed Brad Mondschein, previously the company’s chief operating and legal officer, as chief executive. The investment case is outsourced IT for health systems that cannot staff internally against rising cybersecurity, interoperability and AI-integration complexity. (Link)
  17. BV Investment Partners-backed Imagenet has acquired Analytica Consulting, the California data engineering and artificial intelligence firm, in a transaction that closed on 21 August 2026. Imagenet is moving from transaction-processing BPO toward an end-to-end data and AI solutions position for payers. Analytica Consulting, founded in 2015, brings cloud data warehousing, automated ETL pipelines, enterprise visualisation, data science and governance. The commercial angle is in-situ modernisation: layering pipelines and machine learning models on top of health plans’ existing core systems rather than requiring replacement, and applying prescriptive models to denial trends across digital mailroom, claims adjudication and contact centre lines. The target retains its government, life sciences, manufacturing and education clients. (Link)
  18. Switchboard Health has acquired virtual musculoskeletal provider Livara Health, formerly SpineZone, and closed an oversubscribed equity round of more than $5 million backed by First Trust Capital Partners, Route 66 Ventures, A1 Health Ventures, Allumia Ventures and Martin Ventures. The acquisition converts Switchboard from a referral navigation software layer into a value-based care delivery provider. Livara, founded by orthopaedic spine surgeon Kamshad Raiszadeh, pairs orthopaedic physicians with physical therapists and psychosocial providers, and its outcomes were independently validated by the Validation Institute in 2024 at a 43% reduction in MSK spend, largely through avoided low-value surgery. Switchboard reports routed patient volume up 500% over nine months. This is its second acquisition in under a year after Conduce Health. The raise draws both companies’ existing investors plus new backers. (Link)
  19. WellStack, the Madison, Wisconsin healthcare data platform led by Chief Executive Rich Waller, has acquired DeLorean Artificial Intelligence, the predictive analytics and risk stratification company led by Chief Executive Severence MacLaughlin, to build an end-to-end healthcare decision intelligence platform.WellStack runs an agentic healthcare data platform with a managed data foundation, analytical studio and modular Decision Hubs. DeLorean AI adds continuous evaluation of clinical, claims and operational data to flag emerging risks, predict adverse events and recommend next actions. The combination targets the gap between data aggregation and intervention, moving customers from what happened to what to do about it. Client case studies cite improved patient adherence, reduced avoidable utilisation and revenue optimisation. MacLaughlin framed the merger as necessary for deep integration with health system data lakes and EMRs. (Link)
  20. ALIS, the Chicago-based senior living clinical and operational software platform, has acquired the Ella and elbi technology platforms from TapRoot Interventions & Solutions in its first acquisition. ALIS has grown organically from a clinical EHR into an operating system unifying CRM, clinical, billing, AI and business intelligence; Ella and elbi are its first bought capability. The platforms deliver point-of-care, AI-native guidance to frontline caregivers handling dementia and behavioural episodes, using non-pharmacological, person-centred interventions. The economics sit in two measurable outcomes senior living operators are judged on: fewer high-risk behavioural incidents and reduced psychotropic medication reliance, both increasingly tied to reimbursement and length of stay. The platforms also capture behavioural data for population health reporting. Announced at the buyer’s user conference. (Link)
  21. Globus Medical, Inc. (NYSE: GMED) has acquired Higgs Boson Health, the Durham, North Carolina digital healthcare experience company incubated out of Duke University, to build out its surgical intelligence pillar. What Globus is buying is a team of software developers and AI scientists rather than a revenue base. The acquirer frames the technology as part of a surgical intelligence pillar linking outcomes and analytics in a closed loop across the full episode of care. The stated long-term target is 95% good outcomes at ten years in musculoskeletal surgery, and management is treating patient and provider experience as the missing layer of that ecosystem. The deal follows a second quarter reported on 6 August in which sales grew and non-GAAP EPS guidance was raised. (Link)
  22. Ekoscan Integrity Group, the Eurazeo-backed French non-destructive testing group, has signed a definitive agreement to acquire the US-based NDT Digital business of Carestream Health, Inc., adding the INDUSTREX computed and digital radiography portfolio. Ekoscan is buying Carestream Health’s US NDT Digital unit — computed radiography systems, digital radiography detectors and imaging software under the INDUSTREX brand — plus the commercial, applications and service organisation in Rochester, New York. Radiographic imaging joins the buyer’s existing ultrasound and eddy-current lines, making a multi-method inspection platform for aerospace and defence, oil and gas and power generation. Carestream is narrowing to healthcare imaging. Ekoscan has been an active consolidator, backed by Eurazeo and EDF Pulse Ventures. Closing is expected in the fourth quarter of 2026. (Link)
  23. Golden State Dermatology, the physician-owned platform backed by Sorenson Capital and Yukon Partners, has acquired Summit Dermatology in Colorado Springs, its first move outside California. Golden State Dermatology has been a California story, roughly 45 locations and more than 125 providers built through steady practice tuck-ins with Sorenson Capital and Yukon Partners behind it. Summit Dermatology, led by board-certified dermatologists Kevin Whaley and Jeanne Osborn, is the first out-of-state platform entry and opens the Colorado market. The target offers medical and procedural dermatology including skin cancer screening and Mohs micrographic surgery, and retains its location, phone number and staff. Founder Ed Becker frames the strategy as building the leading comprehensive dermatology network across the Western US. (Link)
  24. Regent Surgical has added Integrated Surgical Center of Arizona, an Avondale multispecialty centre owned by IMS Care, AZ Heart Arrhythmia Associates and Valley GI Consultants, to its ambulatory surgery centre network. Regent Surgical, founded in 2001 and headquartered in Nashville, is a developer and operator of ambulatory surgery centres that has grown from 8 to 32 centres in eight years on site-neutral payment economics. The Arizona addition is a physician-partnership structure rather than an outright buyout: ISCA is owned by IMS Care, the state’s largest independent multispecialty physician group, cardiac electrophysiology group AZ Heart Arrhythmia Associates, and Valley GI Consultants. The strategic value is cardiac migration into outpatient settings across greater Phoenix. Regent also runs a joint venture with Cleveland Clinic. (Link)
  25. Great Point Partners-backed VetnCare has acquired Geary Veterinary Hospital, the Walnut Creek, California practice founded in 1979 and led by Dr. Gillian Hamilton and Dr. Erica Weiss. Great Point Partners, the Greenwich healthcare-only investor, backed VetnCare in 2022; Geary is the seventh acquisition since, and the second in roughly six weeks after Holistic Veterinary Care in Oakland on 14 July. The company has more than doubled in size in three years under that ownership. The model is regional density rather than national scale: VetnCare concentrates in Northern California, and Geary deepens the East Bay position with a practice offering wellness and preventive care, diagnostics and imaging, surgery, dental and senior pet care. (Link)
  26. Gravity 360, Inc., the Covington, Kentucky parent of Gravity Diagnostics, has acquired Med-Lake Laboratory, LLC, a CLIA-certified, CAP-accredited high-complexity clinical laboratory in Milledgeville, Georgia. Gravity 360 is building a regional laboratory platform across the southern United States, and Med-Lake gives it an operating base outside Kentucky for the first time. Founded in 2018, the target serves physician practices, skilled nursing facilities, behavioural health providers, judicial programmes and urgent care clinics across Georgia and Alabama, with a testing portfolio spanning clinical toxicology, blood and clinical chemistry, PCR infectious disease and reference services. Rather than consolidating volume into Kentucky, the buyer is retaining the Georgia laboratory, its team and its courier network as the foundation for further expansion. (Link)
  27. The Landes Group, the Dallas healthcare real estate investment firm, has completed its acquisition of Encore Medical Center in Bryant, Arkansas from Arkansas Heart Hospital and finalised a long-term lease with the University of Arkansas for Medical Sciences, financed with CGA Capital. The Landes Group has closed on a 108,055 square foot, 53-bed hospital and simultaneously locked in its tenant. UAMS gains capacity without deploying capital, paying annual rent reported at roughly $8.16 million with 2.1% escalation and a purchase option in ten years. That structure is the firm’s core strategy: single-tenant, net-leased healthcare assets where ownership is paired with financing that preserves provider capital. Longstanding financing partner CGA Capital supported the transaction, extending a relationship spanning more than $1.2 billion. Arkansas Heart Hospital operates the facility through 30 September, with UAMS assuming control on 1 October. (Link)
  28. Calera Capital-backed Cypress Health Partners has added Boston Sports Medicine’s ten outpatient clinics to the Bay State Physical Therapy network, effective 27 August. Cypress Health Partners, the Calera Capital-backed outpatient physical therapy platform operating across the Northeast, has partnered with Boston Sports Medicine, one of Greater Boston’s most established physical therapy providers. BSM’s ten outpatient clinics join the Bay State Physical Therapy network, expanding access across Massachusetts communities after more than 25 years of referral-base building. The transaction lands as the outpatient PT sector shifts from pure density plays toward a second phase of value creation focused on patient acquisition and reimbursement yield from existing clinical capacity. (Link)

Venture Deals and Other

  1. RA Capital has joined a $120 million Series C for AusperBio Therapeutics that will fund the Phase 3 registrational program for a functional hepatitis B candidate, taking capital raised since 2024 past $340 million.AusperBio, which operates from Hangzhou and California, closed the $120 million Series C on 31 August led by a new strategic investor, with RA Capital Management joining and existing backers HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments returning. Proceeds fund the Phase 3 registrational program and commercialisation work for lead candidate AHB-137, advance next-generation candidate AHB-171, and support combination-therapy development for chronic hepatitis B. The round is the largest venture check in this week’s book and is a China-plus-US therapeutics financing rather than a services deal. (Link)
  2. The Gates Foundation has committed up to $35 million to ProFound Therapeutics, including $20 million initially, to find placental and serum protein targets for preeclampsia and eclampsia. ProFound Therapeutics uses its ProFoundry platform against the expanded human proteome. The Gates money funds discovery of novel proteins expressed in placenta and serum from women with preeclampsia and eclampsia, new drug targets and biomarkers, and a disease-specific AI tool. The initial $20 million is committed now; the balance is contingent on program progress. This is foundation capital rather than a priced venture round, and it sits beside rather than inside the company’s existing equity syndicate. Announced 27 August. (Link)
  3. TJ Parker, general partner at Matrix, has led a $26 million Series A in Metriport, with participation from ARTIS Ventures and Y Combinator, taking the open-source healthcare data infrastructure company to $28.4 million raised. Matrix led the round through TJ Parker, whose stated rationale is channel evidence: he sees dozens of consumer health companies each year and the strongest ones increasingly build on Metriport. The company was founded in 2022 by former AWS engineer Dima Goncharov and Colin Elsinga. The differentiator investors are underwriting is open-source infrastructure against legacy black-box interoperability tools, accessible via a single API, cloud warehouse connection or native EHR application. Customers include Amazon One Medical, Sollis Health and Color Health. Proceeds fund AI chart summarisation and agentic workflows for care teams. (Link)
  4. Define Ventures has led a $25 million Series B in Arintra, with participation from existing investors Peak XV Partners, Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13 and Spider Capital. Define Ventures led the round, taking Arintra’s total funding to $51 million. The investment case rests on measurable throughput: the platform processes more than $5 billion in annual claim value for health systems representing over $50 billion in combined net patient revenue, and reports a 5.1% increase in compliant revenue capture, 32% cost reduction and 43% fewer coding-related denials. Endeavor Health, an early adopter, backed both the Series A and B. Partner Chirag Shah argued no prior solution had been comprehensive enough to move the bottom line. Proceeds fund enterprise expansion and deeper specialty coverage. (Link)
  5. Wing Venture Capital, Initialized Capital, Sozo Ventures, Hawktail, Lightspeed Venture Partners, Third Kind Venture Capital, Liquid 2 Ventures and SV Angel have backed Outer Bio with roughly $23 million as the Cambridge company exits stealth with its Yuna human-skin platform. What the syndicate is funding is a data asset rather than a clinical one: Yuna keeps full-thickness human skin alive and measurable for four weeks against roughly one week for conventional explants, generating longitudinal multi-omic data that improves the machine learning models over time. The commercial route is consumer skincare first, with partnership revenue already flowing. Founded in 2020 by chief executive Michael Polansky, with Stefani Germanotta on the board. The round size and the syndicate signal investors are underwriting a compounding biological dataset rather than a single product launch. (Link)
  6. Saga Ventures has led $22.5 million in seed and Series A funding for Hike Medical, joined by Indicator Ventures, Fifth Down Capital, RiverPark Ventures, strategic investor Orthofeet, Inc. and angels including Monaco chief executive Sam Blond and Jerod Mayo. Max Altman of Saga Ventures led the financing, and his stated thesis is vertical integration: owning the entire value chain end to end rather than layering software on a broken industry. The market economics justify it, with roughly $100 billion spent annually on orthotics, prosthetics and durable medical equipment and, per the company’s own research, 60 cents of every dollar lost to waste, remakes and fraud. Operating metrics already show remake rates cut from one in 15 to one in 400. Strategic investor and commercial partner Orthofeet participated. Proceeds fund hiring in San Francisco and manufacturing in Peoria, Illinois. (Link)
  7. Costanoa has led a $17 million Series A in Onos Health, joined by Flare Capital Partners and strategic investor CVS Health Ventures, the corporate venture arm of CVS Health Corporation (NYSE: CVS). The strategic money matters commercially: Aetna is already a customer, and the company says it is trusted by three of the six largest US health plans. Costanoa partner Amy Cheetham framed behavioural health as one of the largest and least understood categories in healthcare, with wide cost variation and low correlation to quality. Reported outcomes include a 35% improvement in clinical standard adherence and a 6%-plus cut in behavioural health programme costs within twelve months. Proceeds scale the decision-support tools payers use to manage behavioural benefit design and utilisation. (Link)
  8. Neotribe Ventures, Listen and Village Global have funded a $12 million round for Boston-based Legato, which has emerged from stealth to commercialise AI hearing-assistance glasses. Neotribe founder and managing director Kittu Kolluri framed the investment as a bet against the industry’s design orthodoxy, arguing that decades spent making hearing aids invisible has suppressed adoption and that positioning assistance as a style choice is the route to the market. The defensible asset is intellectual property: four granted patents and more than 20 pending applications. The competitive set is formidable, including EssilorLuxottica’s Nuance Audio and hearing features from Apple and Samsung. Proceeds fund a launch in the coming months and further development. (Link)
  9. August Global Partners has led a $10 million convertible note financing for Shape Memory Medical, joined by fellow new investor Taiwania Capital alongside existing backers HBM Healthcare Investments, Earlybird Venture Capital and WexMed II. The convertible structure defers valuation until clinical readouts land. Partner Davian Sim argued clinicians treating aortic aneurysms and dissections have long relied on repurposed materials, and identified an inflection point as two programmes advance. Proceeds fund follow-up in the AAA-SHAPE pivotal trial, fully enrolled at 180 patients across 48 centres, and the FLAGSHIP feasibility study. Both new investors also support Asia-Pacific expansion. HEAL Venture Lab assisted; the note sits ahead of those readouts rather than pricing the company now. (Link)
  10. Redesign Health has provided $2.25 million in seed funding to OmicsBank, the clinical data infrastructure company founded in 2025 by serial entrepreneurs Sumit Sinha and Vijay Goel.Redesign Health is the sole named backer of this seed round. Head of ventures Neil Patel was explicit about the underwriting order, saying the firm backed the founders first and the market second, citing five companies built between them and the relationship-intensive work of winning hospitals one at a time. The asset being capitalised is a deployed data network: infrastructure inside 90-plus hospitals and laboratories across South Asia, Southeast Asia and the Middle East, covering 12.5 million longitudinal records, 30 million DICOM images, six million pathology slides and 500,000 whole-genome sequences. Proceeds fund US and biopharma expansion. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 24th, 2026

LECO_Weekly-Healthcare-News_8-24-2026Download

Healthcare Weekly News and Deals

  1. Francisco Partners to take Weave Communications (NYSE: WEAV) private for $650 million in an all-cash deal at $7.40 per share. The price is a 34% premium to Weave’s Monday closing price, and the company will delist after going public in 2021. The sponsor is buying a vertical platform serving independent medical, dental, optometry and veterinary practices, a customer base most software companies overlook. Weave generated $239 million of fiscal 2025 revenue, up 17%, and $65.5 million in the first quarter of fiscal 2026, also up 17%, yet its market value sits well below the $1.4 billion peak. Francisco Partners raised more than $75 billion and previously bought AdvancedMD for $1.125 billion. (Link)
  2. Universal Health Services (NYSE: UHS) has closed its $835 million debt-financed acquisition of virtual behavioral care provider Talkspace (NASD: TALK). The transaction valued Talkspace at $5.25 per share and was financed with debt. Talkspace keeps its brand and organizational structure, with CEO Jon Cohen reporting directly to UHS President and CEO Marc Miller. The target reported $229 million in revenue, $4.8 million in net income and $15.8 million in adjusted EBITDA in 2025, and runs a virtual network of more than 6,000 behavioral health professionals. Behavioral health already generated about 43% of the buyer’s $17.4 billion 2025 revenue, and UHS expects the deal to be slightly accretive to adjusted net income in the first year after closing. (Link)
  3. Thoma Bravo has to take Accelerant (NYSE: ARX) private at $20.25 per share in an all-cash deal valuing the specialty insurance risk exchange above $4 billion, with existing backer Altamont Capital Partners rolling over. The offer is a 49% premium to Accelerant’s closing price on 12 August 2026. Altamont Capital Partners, which controls around 82% of voting rights, supports the deal, and Altamont and the founders intend to keep an equity interest alongside Thoma Bravo. Thoma Bravo has committed equity, so completion does not depend on additional financing, and shareholders receive a 6% annual ticking fee if insurance regulatory approvals delay closing. Senior partner A.J. Rohde tied the thesis to MGA market growth. (Link)
  4. BioMarin (NASD: BMRN) to acquire Alesta Therapeutics for $275 million BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics to gain ALE1, a clinical-stage oral small molecule for hypophosphatasia. BioMarin will pay $275 million upfront and up to $215 million in development and regulatory milestones. Alesta will spin out all non-ALE1 assets prior to closing. ALE1 is being evaluated in a Phase 1/2a trial and has the potential to become the first oral therapy for the rare genetic bone disease. Closing is expected this quarter. (Link)
  5. Cityblock Health has signed an all-stock agreement to acquire Homeward Health and separately raised a $116 million Series E led by General Catalyst. Financial details of the all-stock acquisition were not disclosed. The $116 million Series E was led by General Catalyst and takes total capital raised past $900 million, against a $400 million 2021 round that set a roughly $5.7 billion valuation. The company says it is not focused on an exit at this time. Cityblock serves almost 200,000 members at $2.2 billion of annualized revenue, up 77% year over year, and the two businesses together will serve nearly 250,000 people. (Link)
  6. R1 to acquire Humata Health, the AI prior authorization company, to extend its Phare Operating System into payer-provider authorization workflows. Pricing was not disclosed and both parties are private. The investment case is denial prevention: prior authorization is a top-three driver of denials, and a KFF survey found one-third of insured adults call it the biggest burden in accessing care. Humata’s agentic workflows match payer policy, build AI-driven clinical bundles and manage requests to final approval, delivering up to a 96% first-pass approval rate while cutting write-offs by 30%, rescheduled appointments by 83% and staff touches by 45%. R1 folds the capability into Phare Intelligence and Payer Atlas and uses it to sell adjacent modules. (Link)
  7. Goldman Sachs Asset Management-backed Advanced Recovery Systems has acquired Promises Behavioral Health from Assured Healthcare Partners. Terms were not disclosed. Promises was previously backed by Assured Healthcare Partners, which converted its debt into equity in late 2021, after BlueMountain Capital Management bought the assets of bankrupt Elements Behavioral Health in 2018. Combined, the company operates 24 facilities in 14 states across medical detox, inpatient, residential and outpatient services. Goldman halted an auction of Advanced Recovery Systems in January, and addiction treatment dealmaking has fallen sharply, with six closings in the first half of 2026 against 19 a year earlier.(Link)
  8. General Catalyst-backed Radial has acquired TMS Health Partners, the MSO behind Mindful Health Solutions, delivering an exit for previous backer Aisling Capital. Terms were not disclosed. Radial is less than a year into its holding period with General Catalyst and has multiplied its clinical footprint with a single transaction. The combination brings Radial to 27 clinics across seven states, most of them from Mindful Health Solutions. The deal also caps a quick turnaround for Aisling Capital. Radial supports clinics with drug and device procurement, billing and RadialOS, an AI clinical decision support tools. (Link)
  9. Flexpoint sells ArtesRx to Linden Capital Partners Flexpoint Ford has completed the sale of ArtesRx, its specialty behavioral health pharmacy platform, to Linden Capital Partners. Formed in 2023, ArtesRx focuses on complex medication regimens for patients with serious mental illness, substance use disorders, and intellectual and developmental disabilities. Under Flexpoint ownership the platform expanded from three pharmacies in a single state to 16 locations across 15 states through organic growth and targeted M&A. Financial terms were not disclosed. (Link)
  10. BPOC partners with Master Medical Equipment and ReNew Biomedical BPOC has made strategic investments in Master Medical Equipment and ReNew Biomedical, sister companies that provide capital equipment distribution, rental, repair and preventative maintenance services to the pre-hospital and post-acute markets. The Jackson, Tennessee-based businesses offer new and refurbished equipment along with biomedical service across a national footprint. Founder and CEO Mark Taylor will continue to lead the companies. Financial terms were not disclosed. (Link)
  11. Truehelm and QHP Capital-backed InformedDNA has divested its Genetic Testing Utilization Management business unit to Zyter, a subsidiary of global technology company Infinite. Terms were not disclosed. InformedDNA is a portfolio company of Truehelm and QHP Capital, and the sale follows the May 2026 divestiture of its Payment Integrity business unit. The sponsors are concentrating remaining capital behind DNAimpact, InformedDNA’s precision health platform, rather than running three businesses at once. The divested unit pairs genetics-trained specialists with evidence-based review for health plans, a capability that grows more valuable as genetic test volume and complexity compound. Truehelm partner and board member Conor Green described the process as sharpening InformedDNA’s focus. (Link)
  12. U.S. Oral Surgery Management, backed by Oak Hill Capital, has partnered with Cottonwood Oral & Maxillofacial Surgery of Albuquerque in its third New Mexico transaction. Terms were not disclosed and both parties are private. USOSM is a management services organization that works exclusively with oral and maxillofacial surgeons and now spans 31 states. The specialist-only mandate is the differentiator against general dental consolidators, and single-practice tuck-ins remain the primary growth mechanism. CEO Doug Drew pointed to clinical reputation, patient care and safety as the selection criteria for the practice. USOSM provides operational, financial and administrative support to surgeons alongside wealth creation. (Link)
  13. Integrated Dermatology has entered the Kentucky market through a partnership with Knuckles Dermatology, which now operates as Integrated Dermatology of Kentucky. Terms were not disclosed and both parties are private. The partnership took effect August 18, 2026 and covers patients in Corbin, Richmond and surrounding southeastern Kentucky communities. Dr. Knuckles continues to practice, and two board-certified family nurse practitioners, Lauren Hayes and Jordan Patterson, join to expand provider capacity. Established in 2004, Integrated Dermatology operates in nearly 30 states and offers dermatologists profit-sharing and full clinical autonomy while handling operational and administrative work centrally.(Link)
  14. Concentra (NYSE: CON) has completed the acquisition of four Minnesota Occupational Health medical centers in the Twin Cities, taking its statewide network to 10 sites. Terms were not disclosed. The four acquired centers sit in Coon Rapids, Eagan, St. Paul Midway and Shakopee, and began operating as Concentra on August 17. Concentra has served Minnesota since 2018 and will now run 10 medical centers across the state. The buyer also plans significant investment in the St. Paul Midway center to make it a regional flagship. The economics rest on density and employer cross-selling across injury care, physical therapy, drug testing and DOT exams. (Link)
  15. Momentum Health Partners has expanded its investment in Desert Pain Specialists, the Rancho Mirage, California interventional pain management practice it first backed in 2023. The amount was not disclosed. The Phoenix-based platform deployed additional capital into Desert Pain Specialists following the acquisition and integration of Dr. Roland Reinhart’s pain management practice. The new capital funds physician recruitment, service line expansion and operational growth across California’s Coachella Valley, where the practice has posted growth in new patient volumes since integrating. Partner Ryan Harper framed the follow-on as confidence in the team. Momentum invests across autism therapy, developmental therapies, behavioral health and specialty ambulatory care. (Link)
  16. SEVA has made a growth equity investment in healthcare price transparency company Serif Health, the first outside institutional capital the San Francisco business since 2020 launch. Terms were not disclosed. The round is Serif Health’s first outside institutional capital since it launched in 2020, and SEVA founder and managing partner Shalin Mehta joins the board. Serif cleans, validates and standardises pricing data from hundreds of payers and thousands of hospitals through its Signal platform, used by more than 250 organisations to benchmark rates, evaluate networks and track market dynamics. Proceeds accelerate sales and expand a pipeline of product features and data APIs, following the 2026 launch of Signal Ask, a plain-language query tool. (Link)
  17. Providence Equity Partners to acquire a majority stake in CheckedUp, with Varsity Healthcare Partners joining as strategic minority. Terms were not disclosed. Providence is acquiring alongside the co-founders, who continue to lead the company, and Varsity Healthcare Partners as a healthcare services-focused minority investor. CheckedUp reaches >17,000 specialty healthcare providers and 15 million patients through waiting-room televisions and interactive exam-room wallboards, and works with most of the top 40 pharmaceutical manufacturers. Providence is underwriting this as a digital out-of-home media asset, consistent with prior positions in OUTFRONT Media, DoubleVerify and Smartly.io. (Link)
  18. Cypress Ridge Capital-backed Cresso Health has partnered with Slate Financial, the Southwest Medicare and health insurance distributor. Terms were not disclosed. Cresso Health is backed by New York-based healthcare investor Cypress Ridge Capital. The logic is distribution roll-up economics. Slate gains access to Cresso’s carrier relationships, distribution infrastructure, proprietary marketing and lead-generation tools and compliance toolkit, while Cresso extends its field presence. CEO Frank Pistone described the goal as an omni-channel, multi-product platform serving the senior market. Cypress Ridge invests exclusively in healthcare with a thematic, growth-oriented approach. (Link)
  19. Rockmont Partners has exited RepScrubs, the automated scrubs dispensing platform, with THL named as acquirer in Healthcare DealHub’s headline. Terms were not disclosed. Healthcare DealHub titles the transaction as THL acquiring RepScrubs from Rockmont Partners, while the deal note itself describes the buyer as undisclosed. Rockmont led a secondary purchase in the business in 2024, making this a short hold. RepScrubs runs an automated scrubs dispensing platform that manages vendor credentialing and enforces policy compliance for perioperative vendors at hospitals and surgery centers. The asset sits in digital and health technology, which has recorded 289 tracked deals year to date. (Link)
  20. Berks Community Health Center to merge with Lancaster-based Union Community Care, a distress-driven nonprofit combination pending regulatory approval. No purchase price applies. Board vice chair Missy Orlando named two financial triggers, starting with a sharp drop in federal Medicaid funding from January that could cost roughly 100,000 Berks County residents their benefits. The center has also struggled to collect patient payments and lost several providers over the past year. Union Community Care operates 25 locations across Lancaster, Lebanon and Chester counties, covering family medicine, urgent care, dental, school-based care, behavioral health and pharmacy. (Link)
  21. Mitsui Chemicals (Tokyo: 4183) has completed its acquisition of Utah-based dental products maker Ultradent Products, making it a wholly owned subsidiary alongside existing dental unit Kulzer. The deal closed on August 14, ahead of the September 2026 schedule, after competition and investment approvals came through early. Mitsui is making oral care the third earnings pillar of its Life & Healthcare Solutions segment and targeting the number two position in global dental materials. The company expects more than $40 million in annual synergy by fiscal 2030. Integration moves the oral care global headquarters to the United States, with Ultradent CEO Dirk Jeffs also taking over as Kulzer CEO while Kulzer’s Chris Holden becomes Chief Strategy and Integration Officer of MC Dental Holdings America.(Link)
  22. Osage Venture Partners-backed Curavit Clinical Research has acquired the CRO assets of Lindus Health, which is shifting to its own therapeutic pipeline as Lindus Therapeutics. Terms were not disclosed. The transaction follows Lindus shifting focus to developing its own pipeline of therapeutic assets. What Curavit bought is European delivery capability, not scale for its own sake: the combined business can now run decentralized, hybrid and traditional trials across North America and Europe under one operational partner. Nate Lentz, managing partner at Osage Venture Partners and a Curavit board member, tied the thesis to sponsors needing more flexible, technology-enabled approaches to generating clinical evidence. CEO Joel Morse positioned the platform against both regional niche CROs and legacy providers. (Link)

Venture Deals and Other

  1. 8VC and Town Hall Ventures have led a $53 million Series D in Hopscotch Primary Care. 8VC and Town Hall Ventures led the round, with existing investors aMoon Fund, Citi Impact Fund, Alumni Ventures and K2 HealthVentures participating and new investors including the Autism Impact Fund, Kleiner Perkins chairman John Doerr, Heritage Provider Network founder Dr. Richard Merkin and the Leon Levine Foundation. Founded in 2021, Hopscotch serves more than 15,000 patients across the rural Southeast, concentrated in western North Carolina. Investors have hard numbers to point at: a Net Promoter Score of 89, patient retention above 90%, medical loss ratio improvement of more than 25 percentage points over two years and profitable operations in western North Carolina. (Link)
  2. Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital have funded Network Bio’s $50 million launch alongside an NVIDIA partnership. Network Bio, a Palo Alto company building AI models trained on human biological data, launched on August 19 with $50 million from investors including Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital. The money funds a research network with Mass General Brigham, the University of Pennsylvania and the University of Colorado Anschutz, supplying tissue and blood samples paired with longitudinal clinical outcomes across immunology, metabolic, cardiovascular and autoimmune disease. Investors are paying for exclusive data access rather than a clinical asset. The launch came with an NVIDIA partnership to scale the models. (Link)
  3. InnovaHealth Partners led Channel Medsystems’ Series C to $30 million, backing the commercial expansion of the Cerene endometrial cryotherapy platform. The Berkeley medical technology company has reached $30 million in an ongoing Series C led by InnovaHealth Partners. InnovaHealth has backed Channel Medsystems since 2021. Proceeds fund commercial organization expansion, physician and patient awareness, professional education and training, clinical evidence generation and market development infrastructure. The raise follows a commercial relaunch of the platform. Founder and Managing Partner Mortimer Berkowitz III pointed to unmet need in women’s health backed by clinical evidence and an experienced leadership team. (Link)
  4. MaxQ Medical raises $31.5 million Series A backed by Olympus MaxQ Medical has closed a $31.5 million Series A led by Atlantic Blue Ventures, S3 Ventures and Olympus Innovation Ventures, with participation from Hillside Capital. The financing advances the company’s transurethral imaging-and-therapy platform for prostate disease, the first spinout from Orchard Ultrasound Innovation. The system combines real-time imaging with tissue-selective therapy in a single outpatient procedure, initially targeting BPH with planned expansion into focal therapy for prostate cancer. Proceeds support clinical program advancement and team expansion. (Link)
  5. Leal Therapeutics announces $30 million Series A extension Leal Therapeutics has completed a $30 million second close of its Series A, adding Eli Lilly as a new investor alongside existing backers OrbiMed, Newpath Partners, Euclidean Capital, SV Health Investors’ Dementia Discovery Fund and others. Proceeds will advance LTX-001, a first-in-class brain-penetrant oral GLS1 inhibitor, through initial readout of its newly initiated Phase 1b/2a trial in schizophrenia, and progress LTX-002 through additional dosing cohorts in an ongoing Phase 1/2 ALS study. (Link)
  6. Werewolf Therapeutics and Ambros Therapeutics announce merger and concurrent $150 million private placement Werewolf Therapeutics (Nasdaq: HOWL) and Ambros Therapeutics have entered an all-stock merger agreement accompanied by an oversubscribed $150 million private placement co-led by RA Capital and Janus Henderson. The combined company, to operate as Ambros Therapeutics and trade as AMBX, will advance neridronate in the pivotal CRPS-RISE Phase 3 trial for Complex Regional Pain Syndrome Type 1. Capital is expected to fund operations through Phase 3 topline results, planned NDA submission and into the first half of 2029. (Link)
  7. Gossamer Bio announces up to $250 million structured private placement Gossamer Bio has arranged a structured private placement of up to $250 million, including $150 million of committed capital, to fund development of seralutinib through potential FDA approval. The financing extends runway for late-stage clinical and regulatory activities surrounding the company’s lead pulmonary arterial hypertension program. (Link)
  8. Biotechnology investor Bob Nelsen has led a $20 million round in Astromech, joined by Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, lifting the Colossal Biosciences spinout to a $3.8 billion valuation. The round was led by Bob Nelsen with participation from Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, bringing total capital raised to $60 million. The valuation is unusual relative to check size, and what investors are buying is founder pedigree and a data position rather than near-term revenue. Astromech was co-founded by Ben Lamm and geneticist George Church, spun out of Colossal Biosciences, and uses 3.8 billion years of evolutionary history as a primary training signal. Longevity is the proving ground, with 46 longevity-associated genes mapped so far. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 17th, 2026

LECO_Weekly-Healthcare-News_8-17-2026Download

Healthcare Weekly News and Deals

  1. Teledyne Technologies (NYSE: TDY) has entered a definitive agreement to acquire Varex Imaging Corporation (NASD: VREX) for $18.90 per share in cash, valuing the X-ray component maker at approximately $1.1 billion. Teledyne is paying roughly $1.1 billion in cash for Varex, extending a medical imaging build-out that began with the 2011 Teledyne DALSA purchase and the 2017 Teledyne e2v deal. Executive Chairman Robert Mehrabian framed the fit as complementary with minimal overlap: Teledyne lacks detectors for high-radiation oncology environments and photon-counting technology, both of which Varex supplies. Both boards approved unanimously; closing is targeted for early 2027 pending regulatory and Varex shareholder approval. Shareholder litigation is reportedly being weighed over whether the price adequately compensates Varex holders. (Link)
  2. Astorg has completed the carve-out acquisition of Thermo Fisher Scientific’s (NYSE: TMO) global microbiology business Astorg has closed a $1.075 billion carve-out of Thermo Fisher’s microbiology unit, structured as cash plus a $50 million seller note. The asset generated $645 million of 2025 revenue inside Thermo Fisher’s Specialty Diagnostics segment, serving over 15,000 customers across more than 100 countries with roughly 2,400 employees at 13 manufacturing and R&D sites. Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, positioned it as the complex-carve-out profile the firm targets. The business will run independently under CEO Dirk Bontridder and rebrand later in 2026. (Link)
  3. Affordable Care, LLC has completed a recapitalization transferring ownership to its existing lenders, cutting debt by approximately $1.0 billion and injecting $75 million of new capital. Affordable Care, the Morrisville, North Carolina dental support organisation, has closed a balance-sheet restructuring that hands ownership to its lender group. The transaction reduces debt by roughly 65%, or about $1.0 billion, provides $75 million of fresh capital and extends maturities to 2031. This is a creditor-led ownership change rather than a sponsor sale: the incoming lender owners are positioned as aligned with a longer-horizon plan. Deleveraging is intended to free capacity for reinvestment in supported practices, clinical capability, operating infrastructure and patient experience — a familiar reset for over-levered DSO platforms. (Link)
  4. PTC Therapeutics (NASD:PTCT) to acquire ST-920 Fabry disease gene therapy program for $111 million upfront plus milestones PTC Therapeutics has been selected as the winning bidder to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. Terms include $111 million upfront and up to $100 million in contingent regulatory milestones. A rolling BLA submission is expected to be completed in Q4 2026, with potential commercial launch in 2027. The deal leverages PTC’s existing rare disease commercial infrastructure. (Link)
  5. Fulcrum Therapeutics (NASD:FULC) and Slate Medicines announce merger agreement with concurrent $245 million private placement Fulcrum Therapeutics and privately held Slate Medicines have entered a definitive all-stock merger agreement. The combined company will operate as Slate Medicines and focus on next-generation migraine therapies, led by clinical-stage candidate SLTE-1009. Concurrently, Slate secured an oversubscribed $245 million private placement from a syndicate including Frazier Life Sciences, Forbion, RA Capital and others, expected to fund operations into 2029. Closing is targeted for the fourth quarter of 2026. (Link)
  6. EnableComp has acquired Helix Advisory, a Cincinnati, Ohio-based revenue recovery firm, to advance Zero Balance Review technology within its complex revenue recovery platform. EnableComp, the Franklin, Tennessee complex revenue cycle management provider, has acquired Ohio-based Helix Advisory. Terms were undisclosed and both parties are private. The acquisition closes a product gap: EnableComp already recovers roughly $3 billion annually across more than 1,000 hospitals in complex claims and denials, but lacked zero balance review — claims already paid, closed and filed, but paid incorrectly. Helix contributes underpayment detection beyond rules-based logic, clinical signal detection and root-cause analytics, folded into the e360 RCM platform. Founder Zack Higbie joins as VP of Revenue Recovery Products, citing early client net revenue improvements exceeding 2%. (Link)
  7. CHG Healthcare has acquired KREWE Anesthesia, a CRNA-founded staffing firm, to expand certified registered nurse anesthetist staffing and managed anesthesia services. CHG Healthcare, the Salt Lake City-area physician and advanced-practice workforce company, has acquired KREWE Anesthesia. Terms were undisclosed and both parties are private. The investment case rests on scarcity: CHG’s own research ranks CRNAs among the hardest advanced-practice roles to fill nationally, with rural hospitals especially dependent on CRNA-led anesthesia to sustain surgical volume. Founded in 2022, KREWE reports roughly 84% annual clinician retention, materially above locum tenens benchmarks. CEO Leslie Snavely framed the deal as capability plus cultural fit. Founders Gavin Baker and Chase Chiasson remain as CEO and President. (Link)
  8. Viome Life Sciences has acquired Circulate Health, the therapeutic plasma exchange provider, adding clinical delivery to its molecular diagnostics and precision nutrition platform. Viome Life Sciences, the Bellevue, Washington preventive health company founded in 2016, has acquired Circulate Health. Financial terms were not disclosed and both are private. The acquisition converts Viome from a diagnostics-and-recommendations business into one owning the intervention layer, expanding the combined platform to more than 200 partner clinics. Circulate contributes physician-guided therapeutic plasma exchange delivered outside hospital settings, with published research associating its protocol with an average 2.6-year biological age reduction and measurable microplastic reduction. Founder Naveen Jain framed the thesis around measurable, repeatable health improvement. Circulate CEO Brad Younggren becomes president of Viome PRO. (Link)
  9. Kyndryl (NYSE: KD) has agreed to acquire Healthcare IT Leaders, LLC, an enterprise IT services provider to hospitals and health systems, to accelerate AI-led modernization for providers and payors. Kyndryl is buying Healthcare IT Leaders to bolt a consulting and application managed services layer onto its existing infrastructure position in U.S. healthcare. Terms were undisclosed. Jamie Rutledge, president of Kyndryl U.S., framed demand as coming from providers under pressure across clinical, operational and workforce systems while maintaining resiliency and compliance. Strategically, this moves Kyndryl up the stack: it already runs large regulated IT environments, and the target deepens relationships with national health systems across federal, academic, pediatric and regional segments. Closing is expected in Kyndryl’s fiscal 2027 second quarter. (Link)
  10. DermCare Management, LLC and U.S. Dermatology Partners have completed a strategic combination creating one of the largest dermatology group practices in the United States, spanning 12 states. DermCare Management and U.S. Dermatology Partners have closed a combination uniting two physician-led platforms across 12 states. Financial terms were not disclosed and both are privately held. The combined organisation will serve more than three million patients annually — DermCare contributes over 270 providers and more than one million patients across Florida, Texas, Virginia, North Carolina and California, while USDP treats over two million patients across nine states. Scale economics drive the rationale: national clinical trial infrastructure, expanded provider education and shared practice technology. DermCare founder Jeffrey Schillinger becomes Executive Chair; USDP’s Paul Singh leads as President and CEO. (Link)
  11. LLR Partners and LNK Partners-backed Schweiger Dermatology Group has acquired Saratoga Dermatology, expanding its footprint across the greater Albany, New York market. Schweiger Dermatology Group, backed by private equity sponsors LLR Partners and LNK Partners, acquired Saratoga Dermatology on August 5, 2026. Financial terms of the private transaction were not disclosed. The target operates outpatient clinics in Saratoga Springs and Clifton Park under Drs. Jean Buhac, Christopher Heath and John Buhac, delivering medical, surgical and cosmetic dermatology. The sponsors’ model is density plus centralisation: SDG already runs more than 65 offices and roughly 200 providers across the Northeast, and the addition concentrates upstate New York coverage while folding the practice into shared operational infrastructure. (Link)
  12. Little Rock, Arkansas-based Rock Dental Brands has partnered with TLC Pediatric Dentistry & Orthodontics, a Tampa, Florida specialty practice led by Dwight Sanjuan, DMD, and Robertzon Guloy, DMD. Rock Dental Brands has added TLC Pediatric Dentistry & Orthodontics in Tampa, extending its multi-specialty DSO platform into the Florida market. Deal terms were not disclosed and both parties are private. Launched in 2003, TLC pairs pediatric dentistry with orthodontics under two clinician owners, a dual-specialty configuration consolidators favour because it captures a patient across a longer treatment arc and internalises referral flow. Dr. Sanjuan holds memberships in the American Academy of Pediatric Dentistry, the Florida Academy of Pediatric Dentistry and the International Association of Pediatric Dentistry. The transaction reflects continued single-practice tuck-in activity in dental support organisations. (Link)
  13. DuneGlass Capital-backed Phase 1 Equity has acquired a multi-site orthodontic practice in North Dakota, marking its fourth practice addition of 2026 and its 23rd doctor. Phase 1 Equity, the Chicago-headquartered doctor-owned platform launched by DuneGlass Capital in 2022, has added a multi-site North Dakota orthodontic practice. Terms were undisclosed. The transaction is Phase 1’s fourth addition of 2026, its first in North Dakota, and lifts the platform to 23 doctors across 33 locations nationally. The differentiator is the sponsor’s proprietary Doctor Equity model, under which participating orthodontists and pediatric dentists retain full clinical and practice-level decision rights while accessing private-equity economics and network scale. DuneGlass Managing Partner Ryan Graham co-founded the platform as an alternative to conventional dental consolidation. (Link)
  14. WindRose Health Investors, LLC has completed the recapitalization of Verified Clinical Trials, LLC, the clinical trial subject registry provider, and appointed Howard Miller as Chief Executive Officer. WindRose Health Investors, the New York healthcare private equity firm managing roughly $8 billion, has recapitalized Verified Clinical Trials. Terms were undisclosed. Partner CJ Burnes described VCT’s platform as proactively reducing downstream risk across the clinical research chain. The underwriting logic is infrastructure rather than therapeutics: VCT’s secure global database detects duplicate enrolment and protocol violations at screening, and sixteen years of proprietary data assets create a defensible position. Capital funds data and analytics expansion for sponsors, CROs and trial sites. Founders Mitchell Efros, MD and Kerri Weingard, ANP remain actively involved post-close. (Link)
  15. Integrity, LLC has partnered with Meraz Health Insurance Agency, the Temecula, California Medicare-focused independent marketing organization led by Manuel “Manny” Meraz. Integrity, the Dallas-headquartered distributor of life and health insurance and provider of wealth and retirement solutions, has added Meraz Health Insurance Agency to its partner network. Financial details were not disclosed and both parties are private. The transaction follows Integrity’s established roll-up pattern in independent marketing organizations, where acquired agencies gain access to the IntegrityCONNECT AI platform, Ask Integrity voice assistant, marketing infrastructure and carrier breadth. Meraz brings a decade-long Medicare Advantage, prescription drug and Medicare supplement book with deep Latino community distribution — a demographic channel with structural growth in Medicare enrolment. (Link)
  16. Denver-based Mountaingate Capital has fully exited its investment in Relevate Health, the Cincinnati, Ohio-based healthcare commercialization platform, after a six-year partnership. Mountaingate Capital, a lower-middle-market firm partnering with founders and entrepreneurs, has exited Ohio-based Relevate Health, closing August 5, 2026. Terms were undisclosed and the buyer was not identified. Mountaingate first invested in 2020, and the value-creation plan ran through four add-on acquisitions plus investment in Relevate’s proprietary ELE Decision Engine, product suite, infrastructure and leadership team. Co-Founder and Managing Director Bruce Rogers framed the outcome as validation of the original thesis. The firm characterises it as another strong result in tech-enabled, analytics-driven marketing services — a sector where Mountaingate has now realised repeat exits. (Link)
  17. Global systems integrator Myriad360 has acquired the assets of healthcare-focused F3 Technology Partners, pushing the combined platform past the $1 billion annual revenue. Myriad360, the West Deptford, New Jersey-based systems integrator, has purchased the assets of F3 Technology Partners, a West Hartford, Connecticut provider with a longstanding healthcare and financial services vertical. Terms were not disclosed and both are private. The deal follows Myriad360’s February 2026 acquisition of Ohio-based AdvizeX Technologies, which alone created a roughly $900 million run-rate platform; F3 carries the combined business across $1 billion. The strategic driver is channel consolidation — vendor programmes increasingly favour scaled partners, and healthcare vertical depth commands premium positioning in a fragmented integrator market. (Link)
  18. Gridiron Capital, LLC has partnered with van den Boom & Associates, the San Diego-based outsourced back-office services provider to emerging life sciences companies, under founder Esther van den Boom’s continued leadership. Gridiron Capital, the New Canaan, Connecticut firm focused on founders, entrepreneurs and management teams, has invested in van den Boom & Associates. Financial terms were not disclosed. The deal advances Gridiron’s Outsourced Pharma Services Thematic Area of Expertise and builds on prior healthcare and pharma-adjacent services investments. Principal Aaron Stoppelmann framed the thesis around two converging trends: growth in venture-backed life sciences companies and their preference for specialised operational partners. vdB&A serves 160-plus active clients with 150-plus professionals across finance, HR, contract management, compliance and a newly launched IT managed services line. (Link)
  19. Marlin Equity Partners-backed Radar Healthcare has acquired patient experience and patient-reported outcomes platform Cemplicity, following its earlier purchase of EIDO Healthcare. Radar Healthcare, the quality, risk and compliance software provider backed by Marlin Equity Partners, has acquired Cemplicity. Terms were undisclosed and both parties are private. The sponsor thesis is adjacency stacking rather than scale: Cemplicity contributes patient experience measurement, patient-reported outcomes and real-time patient insight, which Radar pairs with its existing quality, risk and improvement workflows. Chief Executive Edward Bellamy positioned the logic as connecting what patients report to the workflows needed to act on it. The deal follows Radar’s acquisition of digital consent provider EIDO Healthcare, extending a buy-and-build across the quality-and-safety software stack. (Link)
  20. The Riverside Company adds Yellow Emperor to Western Botanicals The Riverside Company has made Yellow Emperor its first add-on investment for portfolio company Western Botanicals. The Eugene, Oregon-based CDMO specializes in custom liquid dietary supplement formulations, providing end-to-end services from ingredient sourcing through manufacturing, bottling and packaging. The combination deepens Western Botanicals’ liquid capabilities and strengthens its position as a formulator and manufacturing partner for health and wellness brands. (Link)
  21. Sarnova, Patricia Industries portfolio company, acquires Mercury Medical Sarnova, a national specialty distributor of emergency medical services and acute care products, has acquired Mercury Medical. The Clearwater, Florida-based company designs, manufactures and distributes critical care and emergency medical devices. The deal expands Sarnova’s product portfolio across its Bound Tree Medical, Cardio Partners, Emergency Medical Products and Tri-anim Health Services units. (Link)
  22. Livingbridge has put teleradiology group Everlight Radiology up for sale at around $1 billion, with Radiology Partners reported to be the front-runner UK mid-market firm Livingbridge is running a roughly $1 billion sale of Everlight Radiology. The process is now in its late stages, with Radiology Partners reported to be leading. An Everlight exit would hand Livingbridge a large realisation from a cross-border teleradiology asset, while a Radiology Partners win would extend the US-based radiology platform’s reach into Australian and UK night-hawking volumes. Radiology reading remains one of the most actively consolidated healthcare services niches for private capital. (Link)
  23. Curium acquires Abscint, expanding its PET radiodiagnostic pipeline in oncology Curium, a global radiopharmaceutical company, has completed the acquisition of Abscint SA, a Belgian clinical-stage company developing PET imaging agents for oncology. The deal adds ABS-011, an investigational gallium-68-labeled PET tracer targeting HER2 that is currently in a Phase 2b trial. Curium gains global rights to develop, manufacture and commercialize the asset, strengthening its radiodiagnostic capabilities in breast and gastric cancers. (Link)

Venture Deals and Other

  1. Soleus Capital has led a $110 million Series C and debt financing in Bridge to Life Ltd., with Lauxera Capital Partners participating and Soleus Capital Credit Opportunities Fund providing the debt tranche. Soleus Capital, the Greenwich firm with roughly $3.5 billion in assets under management, led the equity alongside Lauxera Capital Partners, which manages over $1 billion across 14 healthtech portfolio companies; Bridge to Life directors, officers and employees also participated. Partner Ben Lund cited the pairing of an established preservation franchise with a newly FDA-cleared perfusion platform. Proceeds refinance the Perceptive Credit Funds facility — cutting leverage and interest cost — and fund the VitaSmart HOPE System commercial build-out to every U.S. transplant center, plus a viability assessment tool and multi-organ pipeline. (Link)
  2. Bessemer Venture Partners has led a $50 million Series B in Flagler Health, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners and Offscript. Bessemer Venture Partners led the $50 million Series B for New York-based Flagler Health, taking total funding to $63 million. Partner Steve Kraus pointed to the founding team’s combination of healthcare operations experience, clinical authority and AI expertise applied to a large underserved market. Investors are backing demonstrated unit economics rather than promise: in under three years Flagler has scaled to thousands of providers across more than 36 states, delivering an average $164,000 in additional annual revenue per provider, with 87% of patients reporting improvement. Musculoskeletal care represents over $400 B in annual U.S. spend. (Link)
  3. OG Venture Partners and M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany (ETR: MRK), have co-led a $36 million Series A in Remepy, joined by NFX, Qumra Capital, Tadmor Group, TechAviv and Vine Ventures. OG Venture Partners and M Ventures, the strategic venture arm of Merck KGaA (ETR: MRK), led Remepy’s $36 million Series A, lifting total capital raised to $62 million. The strategic investor’s participation is notable given Merck KGaA’s existing hybrid drug development partnership with Remepy covering multiple indications, starting with rare tumours. Proceeds fund a global Phase III trial of lead asset Hybridopa in Parkinson’s disease, commencing in the fourth quarter of 2026, following positive Phase IIa motor and non-motor data. Investors are betting on evolving U.S. regulatory frameworks for drug-software combination products. (Link)
  4. Redmile Group, Vsquared Ventures and Kindred Capital have co-led a $25 million seed round in Bios Life, which signed a multi-year data alliance with Tempus AI (NASD: TEM). Redmile, Vsquared Ventures and Kindred Capital led the $25 million seed for Bios Life, joined by healthcare and technology investors across the United States and Europe — an unusually deep syndicate for a company emerging from stealth. Investors are underwriting a founder-pedigree and data-moat thesis: CEO Ryan Richardson was BioNTech’s chief strategy officer and chaired InstaDeep, and the company holds commercial rights to the Nucleotide Transformer genomics foundation model. The Tempus alliance supplies de-identified multi-modal oncology data for training, with Tempus-owned Ambry Genetics adding hereditary testing. Launch is slated for second-half 2026. (Link)
  5. Battery Ventures has made a significant growth investment in Vetspire, the AI operating system for veterinary practices, carving it out as a standalone company from Thrive Pet Healthcare. Battery Ventures, a global technology-focused investment firm founded in 1983, is backing Vetspire as an independent business, with Thrive Pet Healthcare retaining no ownership going forward while remaining a long-term customer. Terms were undisclosed. General Partner Chelsea Stoner cited timing: Covid-era adopted pets are aging into higher care needs. Battery brings a track record in specialty-healthcare EHR and practice-management platforms including Brightree, ClearCare, ContinuumCloud, Curve Dental and WebPT. Vetspire runs at more than 800 hospitals and clinics; Zachary Seely joins as CEO. (Link)
  6. XiFin, Inc. has made a strategic investment in Denver-based Notable Systems as part of Notable’s Series B financing, alongside a multi-year agentic AI alliance across revenue cycle management. XiFin has invested in Notable Systems’ Series B while committing to a multi-year technology alliance. The investment amount was not disclosed and both companies are private. Executive Chair and CEO Lâle White framed the capital commitment as reinforcing XiFin’s position in intelligent revenue cycle management. Notable’s document intelligence will be embedded into the XiFin Empower AI RCM ecosystem, targeting requisitions, prescriptions, medical records and payer correspondence. Notable serves enterprise DME providers including Orthofix (NASD: OFIX) and National Seating & Mobility. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 10th, 2026

LECO_Weekly-Healthcare-News_8-10-2026Download

Healthcare Weekly News and Deals

  1. Hinge Health, Inc. (NYSE: HNGE) has signed a definitive agreement to acquire virtual-first digestive care provider Cylinder Health, Inc. for $105 million in cash. Hinge Health (NYSE: HNGE) is deploying $105 million of cash to enter gastrointestinal care, a category it sizes at $135 billion of annual U.S. medical spend affecting roughly one in four adults. Cylinder brings nearly 100 clients across two million lives, relationships with two of the three largest PBMs and three of the top five health plans by self-insured share, and more than 150,000 patients treated with a clinically validated ROI. The rationale is cross-sell economics: Hinge cites high comorbidity with its existing MSK and migraine populations. An integrated GI program launches in 2027; closing is expected in the third quarter of 2026. (Link)
  2. KKR has agreed to acquire Integer Holdings Corporation (NYSE: ITGR), the Plano, Texas-based medical device contract development and manufacturing organization, in an all-cash take-private valuing the company at an enterprise value of approximately $5.7 billion. KKR is paying $127.00 per share in cash for Integer Holdings (NYSE: ITGR), a 51.8% premium to Integer’s April 29, 2026 close and 28.8% over its 30-day VWAP as of July 31, 2026. The deal follows a board-led strategic review launched in April and is financed with equity from KKR-managed funds plus committed debt, with no financing contingency. KKR, which reported $796 billion of assets under management at quarter end, deepens a healthcare book that already includes the 2018 Envision take-private, and plans to establish an employee ownership program at Integer. Closing is expected by year-end 2026 and Integer will delist from the NYSE. (Link)
  3. Teleflex Incorporated (NYSE: TFX) has completed the divestiture of its OEM business to private equity firms Montagu and Kohlberg for $1.5 billion in cash, with the unit relaunched as Ingenyx. Montagu and Kohlberg have closed their $1.5 billion all-cash purchase of Teleflex’s (NYSE: TFX) contract manufacturing arm, carved out via Lotus US Bidco Inc. and rebranded Ingenyx. Teleflex estimates approximately $1.25 billion in after-tax proceeds and will apply them to $800 million of debt reduction and completion of a $1 billion share repurchase authorization. The sale was first announced in December 2025 alongside the Acute Care unit at $2.03 billion of combined value. For Teleflex, the exit concentrates the portfolio on Vascular Access, Interventional and Surgical; for the sponsors, it delivers a standalone medtech CDMO platform. (Link)
  4. Nordic Capital has agreed to carve out BWX Technologies, Inc.’s (NYSE: BWXT) medical business, including BWXT Medical and Kinectrics’ stable medical isotopes unit, in a transaction valued at up to $800 million. Nordic Capital, which manages roughly EUR 39 billion and runs a dedicated healthcare franchise, is acquiring BWXT’s (NYSE: BWXT) radiopharmaceutical platform in a carve-out valued at up to $800 million. BWXT has roughly tripled the unit’s revenue since buying it in 2018 and will retain a meaningful minority stake, allowing it to redeploy capital toward nuclear national security and commercial nuclear power. Partner Christian Hedegaard framed radiopharmaceuticals as sitting at the intersection of Nordic’s pharmaceutical and life sciences track record. The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026. (Link)
  5. iRhythm Technologies, Inc. (NASD: IRTC) has agreed to acquire San Jose-based wearable biosensor company VitalConnect for $287.5 million, comprising $237.5 million in cash and approximately $50 million in iRhythm stock. iRhythm (NASDAQ: IRTC) is paying $287.5 million for VitalConnect, a private FDA-cleared biosensor platform running at an approximately $65 million annual revenue run rate, in a move that pushes iRhythm deeper into mobile cardiac telemetry. The deal was disclosed alongside 2Q26 results showing 20.1% year-over-year revenue growth and a $50 million patent settlement with Baxter. BTIG’s Marie Thibault called the deal surprising and expects mixed investor reaction, flagging concerns it could mask an MCT slowdown while noting the timing likely reflects VitalConnect’s capital needs. Management expects revenue contribution from 2027; closing is targeted by year-end. (Link)
  6. Jazz Pharmaceuticals (NASD:JAZZ) to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones Jazz Pharmaceuticals (NASDAQ: JAZZ) has agreed to acquire privately held Actio Biosciences for $820 million in cash upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy targeting KCNT1+ epilepsy, a rare and severe developmental epileptic encephalopathy with no FDA-approved treatments. Jazz will also take a minority stake in a new spin-out company focused on other genetic rare neurological diseases. Closing is expected in the fourth quarter of 2026. (Link)
  7. Tarsus Pharmaceuticals (NASD:TARS) to acquire Alkeus Pharmaceuticals for approximately $450 million upfront plus up to $350 million in milestones Tarsus Pharmaceuticals (NASDAQ: TARS) has entered a definitive agreement to acquire Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a Phase 3 oral investigational therapy for Stargardt disease. Consideration consists of roughly $270 million in cash and $180 million in Tarsus stock, plus up to $350 million in regulatory and commercial milestones and low single-digit royalties. The asset has Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations; Phase 3 NORTHSTAR topline data are expected in the second half of 2029. Closing is anticipated in 2026. (Link)
  8. Supernus Pharmaceuticals (NASD:SUPN) and Indivior Pharmaceuticals (NASD:INDV) to merge in all-stock transaction, creating a diversified CNS company Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) have agreed to combine in a tax-free all-stock merger of equals. The combined company, to be named Supernus, Inc., is expected to generate approximately $2.2 billion in pro forma annual revenue and $125 million in annual cost synergies. Indivior stockholders will receive a $1 billion special cash dividend immediately prior to closing and will own about 56.5% of the combined entity. Jack Khattar will serve as CEO. Closing is targeted for the fourth quarter of 2026. (Link)
  9. Keensight Capital-backed Isto Biologics has acquired NovaBone Products LLC from Halma plc (LSE: HLMA) for approximately $60 million, expanding its bone graft substitutes platform. Keensight Capital, a pan-European growth buyout manager, has supported portfolio company Isto Biologics in acquiring NovaBone from Halma (LSE: HLMA) for a total consideration of roughly $60 million on a cash-free, debt-free basis. Completed just ten months after Keensight’s investment, this is Isto’s first bolt-on and the opening move in an explicit buy-and-build toward a transatlantic orthobiologics leader. Partners Amit Karna and David Piccoli cited product breadth and geographic reach as the value drivers. Alachua, Florida-based NovaBone sells bioactive glass synthetic grafts in over 40 countries across spine, orthopedic, trauma, extremities and dental applications. (Link)
  10. Eir Partners Capital has made a strategic investment in ClaimsBridge, which simultaneously acquired dialysis cost-containment specialist DialysisPPO, expanding its healthcare cost management ecosystem. Eir Partners Capital, a private equity firm focused on healthcare technology and tech-enabled services, has backed Arnold, Maryland-based ClaimsBridge in a dual transaction announced August 6, 2026. Terms were undisclosed. Founder and CEO Brett Carlson framed the thesis around ClaimsBridge sitting at the point in the claims workflow where pricing and routing decisions are made. The capital funds product development, platform expansion and further M&A. Alongside the investment, ClaimsBridge acquired DialysisPPO, founded 2006, whose patented program has saved payers over $325 million by capturing Medicare savings on dialysis claims without the usual thirty-month coordination period. (Link)
  11. The Difference Card, a Stone Point Capital portfolio company, has acquired healthcare analytics business HealthCorum, expanding its data, provider-scoring and AI navigation capabilities. The Difference Card, the employer health benefits cost-containment platform acquired by Stone Point Capital from Northlane Capital Partners in 2025, has bought HealthCorum. Financial terms were undisclosed. The acquisition adds provider quality scoring across more than 1.5 million providers and over 90 medical subspecialties, folding into the company’s Provider Lookup Manager Tool, plus an AI Navigator supporting natural-language provider search. The strategic logic is margin-relevant: pairing plan-design savings with steerage toward higher-quality, lower-cost providers deepens the value proposition to self-funded employers facing rising trend, and moves the platform from pure cost containment toward navigation. (Link)
  12. Beacon Behavioral Partners, based in Louisiana, has partnered with AR Psychiatric and Counseling Center, marking the physician-led behavioral health expansion into Georgia. Beacon Behavioral Partners, a Baton Rouge-headquartered network of independent interventional psychiatric practices, has entered Georgia through a partnership with AR Psychiatric and Counseling Center. Financial terms were undisclosed and both organisations are private. ARPCC operates two locations serving Valdosta, Tifton and South Georgia under co-lead psychiatrists Anil Gupta, MD, and Bhavesh Patel, MD, who retain the physician-led model. SVP of Business Development Todd Mudd positioned the transaction as preserving clinical autonomy while funding growth. Beacon’s model removes operational burden in exchange for scale, and the platform reported more than 250 providers across 45 locations as of its last disclosed count. (Link)
  13. Bookmark Medical, a provider-led platform has acquired Village Medical Michigan, including Huron Valley Practice Affiliates,  expanding to Michigan and four other states. Bookmark Medical, the Nashville-based primary care platform rebranded from Village Medical earlier in 2026, closed its Michigan entry effective August 3, 2026. Financial terms were undisclosed and both parties are private. The transaction adds seven primary care practices, a diagnostic center and Huron Valley Practice Affiliates, an independent physician organization, comprising roughly 40 providers, over 350 employees and more than 40,000 patients across Southeast Michigan. CEO Benson Sloan and Chief Physician Executive David Hatfield framed the deal around density and provider support. Bookmark now operates across Arizona, Massachusetts, Michigan and Tennessee, with the physician organization adding affiliated-physician reach beyond owned clinics. (Link)
  14. Frazier Healthcare Partners portfolio company LUX Infusion has acquired Infuse IQ, a Cody, Wyoming-headquartered independent infusion therapy provider operating six ambulatory infusion centers. LUX Infusion, the Frazier Healthcare Partners-backed platform formerly known as BioMatrix Specialty Infusion Pharmacy, has added Infuse IQ in its latest tuck-in. Terms were undisclosed. The sponsor’s thesis is site-of-care migration: as payers push infusion out of hospital outpatient departments, LUX is assembling an omnichannel network spanning home infusion and ambulatory centers, now reaching from Alaska to the Southeast. Infuse IQ contributes six clinics serving more than ten specialties with broad payer acceptance and co-pay assistance programs. CEO Brian Zweben cited LUX’s clinician-led model and technology investment as the fit; this follows recent Northeast Infusion Therapy and First Choice deals. (Link)
  15. Versant Diagnostics has acquired American Dermatopathology Laboratory, LLC, a dermatopathology practice based in Centerville, Ohio, and welcomed dermatopathologist H. Nicholas Shamma, MD. Versant Diagnostics, a Grapevine, Texas independent physician services company, has acquired Ohio-based American Dermatopathology Laboratory, extending a national roll-up of subspecialty anatomic pathology practices. Financial terms were not disclosed and both parties are private. The Ohio practice folds into Versant DermPath, the company’s dermatopathology-focused entity, with Dr. Shamma joining as an integral partner. CEO Jim Billington positioned the transaction as building one of the country’s strongest dermatopathologist networks and expanding specialist access. The deal follows Versant’s 2025 expansion into Georgia and reflects a consolidation model that pairs digital pathology infrastructure with physician equity participation. (Link)
  16. Gastro Health has finalized a partnership with Center for Advanced Gastroenterology, a four-physician Central Florida practice. Gastro Health, a national single-specialty digestive and liver health group, has added Center for Advanced Gastroenterology, which operates offices in Maitland and Lake Nona with four board-certified gastroenterologists and two advanced practice providers. Financial terms were undisclosed and both parties are private. CEO Alan Oliver framed the strategy as extending the network by collaborating with high-quality practices in existing markets, and the platform explicitly characterises the transaction as an acquisition milestone in its growth plan. The eighth Orlando-area deal reflects a density-first consolidation approach that concentrates referral flow and ambulatory endoscopy volume within defined geographies. (Link)
  17. Unite Us has acquired Vircho Health, a performance, quality and financial analytics platform for community care networks, strengthening its health and community care infrastructure. Unite Us, the social care coordination network, has acquired Vircho Health including its full team led by co-founders Craig Manson and Evan Jones. Financial terms were undisclosed and both companies are private. The deal responds to a funding shift in social determinants of health, where government payers, health plans and foundations increasingly demand proof of outcomes and quantifiable financial return rather than closed-loop referral confirmation alone. Unite Us brings a thirteen-year dataset of nearly 125 million care connections; Vircho adds dollar-level expenditure tracking and per-organisation performance reporting. Vircho tools already run alongside Unite Us in North Carolina through Impact Health. (Link)
  18. Ascend Learning has acquired Teaching Assignment Management System (TAMS), a cloud-based faculty workload platform built at Duke University. Ascend Learning, a healthcare and learning technology company, has acquired TAMS, used by more than 70 institutions including Johns Hopkins, Texas A&M and Marquette. Terms were undisclosed. CEO Lissy Hu framed the rationale as owning the full continuum from faculty planning through student outcomes, building on ATI Nursing Education’s penetration of more than 60% of U.S. nursing schools. The strategic value is cross-sell into an installed base at a moment when nursing programs face faculty shortages and enrolment pressure. Founder David Parrish cited Ascend’s distribution reach as the deal driver; the platform replaces spreadsheet-based assignment and workload processes. (Link)
  19. Copley Equity Partners portfolio company FMG Leading has acquired Washington, D.C.-based market intelligence and strategic advisory firm BroadBranch Advisors, adding competitive and customer intelligence capabilities to its healthcare advisory platform. FMG Leading, a Philadelphia-based strategic advisory firm founded in 1984 and backed by Copley Equity Partners since 2022, closed its purchase of BroadBranch Advisors effective July 31, 2026. Terms were undisclosed and both firms are privately held. The sponsor thesis is capability stacking rather than scale: FMG advises investor-backed healthcare executives on growth and value creation, and BroadBranch contributes an “outside-in” competitive and customer intelligence practice, combining market insights with organisational health data on one platform. CEO and Chairman Matt Brubaker cited rising client demand for faster translation of forward-looking intelligence into action. BroadBranch Managing Partner Courtney Matson continues with the combined business. (Link)
  20. Tortuga Growth Partners has made a strategic investment in Advanced eClinical Training, an online healthcare certification and workforce development provider, through Tortuga Growth Partners Fund I, L.P. Tortuga Growth Partners, a New York private investment firm built around disciplined buy-and-build, has invested in Advanced eClinical Training out of its debut fund, extending the build-out of its healthcare vertical. Terms were undisclosed. Managing Member Ashray Prasad framed the thesis as backing founders addressing large, enduring problems with structural tailwinds, citing an American Hospital Association projection of a 3.2 million-worker healthcare shortage this year. Senior Managing Director Walt Vester will help scale the platform. Tortuga has assembled a board and advisory group including operating partners Michael O’Neil, who becomes executive chair, Vester and Marty DeMonte alongside co-founders Shay and Shabnam Safarzadeh. (Link)
  21. GreyLion and Vestar Capital Partners portfolio company 360training.com, Inc. has acquired select assets of seven San Antonio-based compliance training brands, including American Health Training and National OSHA Foundation. 360training, an Austin-based regulated online training platform owned by GreyLion and Vestar Capital Partners, has executed another add-on in a rapid buy-and-build cadence that already includes ACLS Medical Training, Canadian Food Safety Group and the On The Fly brands in 2026 alone. Terms were undisclosed. The acquired portfolio spans healthcare, OSHA and workplace safety, food handling, forklift operations, hazardous materials, defensive driving and transportation safety, broadening the sponsors’ multi-industry compliance footprint across the United States and Canada. The strategy is consolidation of fragmented, mandatory-certification niches where regulatory complexity supports recurring, non-discretionary demand. (Link)
  22. Lee Health has acquired Gardner Orthopedics, a Fort Myers orthopedic practice, expanding the nonprofit system’s musculoskeletal service line across Southwest Florida. Lee Health, a Southwest Florida nonprofit health system, has acquired Gardner Orthopedics, absorbing all 75 employees including five physicians alongside nurses, physical therapists and medical assistants. Financial terms were not disclosed; as a nonprofit system acquisition of a physician practice, no sponsor capital is involved. Kris Fay, Chief Administrative Officer of LPG and Ambulatory Care, positioned the deal as expanding access to orthopedic and musculoskeletal care. The Winkler Avenue facility remains operational, strengthening outpatient footprint. The transaction supports the Lee Health Musculoskeletal Institute build-out at a time of sustained population growth in the region. (Link)
  23. Philips International has completed the acquisition of the healthcare consulting, technology and recruiting businesses of The Nash Group, Inc., Advance Solutions International, Inc. and Nursing Advisory Services LLC. Philips International, a Great Neck, New York privately held investment company has closed its purchase of the Nash healthcare businesses. Financial terms were undisclosed. Adrian Miller, Managing Director of Corporate M&A at Philips International, cited the platform’s expertise, longstanding customer relationships and differentiated workforce solutions, and said the buyer will invest in people, technology, business development capability and operating infrastructure. Established in 1992, The Nash Group serves hospitals across staffing optimisation, acuity and workload analysis, operational performance improvement, hospital technology, and domestic and international nurse recruitment. (Link)
  24. Codis completes acquisition of Catalent’s Nottingham, UK facility Codis, a global CDMO specializing in spray drying and amorphous solid dispersions, has closed its acquisition of Catalent’s Nottingham, UK facility. The site adds oral solid dose development, clinical supply and small-scale commercial manufacturing capabilities, complementing Codis’ commercial-scale spray drying operations in Haverhill. The combination creates an integrated European pathway from early development through commercial intermediates and finished dose forms. Financial terms were not disclosed. (Link)
  25. Nexa Equity portfolio company Facility Grid has acquired PingCx, an autonomous commissioning platform for building automation systems, and launched a unified building lifecycle software platform. Facility Grid, a Waltham, Massachusetts commissioning and operational readiness software provider backed by San Francisco-based growth equity firm Nexa Equity, has acquired PingCx. Terms were undisclosed. Nexa manages more than $1 billion in assets and runs a concentrated investment approach pairing investors with operators. The acquisition converts Facility Grid from a point commissioning tool into a three-product platform, with PingCx becoming FG Validate alongside FG Construct and FG Sustain, the latter launching in September. CEO Daniel Russo positioned the strategy around owning the system of record across a building’s full life rather than only its construction phase. (Link)
  26. Sheridan Capital Partners has completed its investment in Carolina Components Group, a Durham, North Carolina supplier of custom-engineered bioprocessing assemblies to biopharmaceutical manufacturers. Sheridan Capital Partners, a healthcare-dedicated private equity firm investing $30 million to $150 million per manufacturing deal out of its $575 million Fund III, has closed a private investment in Carolina Components Group. Financial terms were undisclosed. Partner Michael Bernard described CCG as the output of a multi-year thesis in the pharmaceutical manufacturing supply chain, with the deal led alongside Sean Dempsey and Conor Kolstad. Founder John Cooling and other leaders retain meaningful ownership and Cooling joins the board, while Maurice Phelan, formerly President of Sartorius North America, becomes CEO. CCG serves over 250 biopharma and CDMO customers. (Link)
  27. Neuronetics, Inc. (NASD: STIM) and second-largest shareholder Jorey Chernett of Pointillist Family Office have reached an agreement establishing a path to board representation, with largest holder Madryn Asset Management, LP reaffirming its support. Neuronetics (NASDAQ: STIM) has resolved a months-long campaign by Jorey Chernett, whose Pointillist Family Office holds 14.12% of shares outstanding and 10,588,988 shares with sole voting and dispositive power. Chernett had criticised chronic underperformance since the $45 million Greenbrook TMS acquisition in late 2024 and pushed for a sale of the TMS device business; the company is not pursuing that route. Under the understanding, Chernett may recommend a new board appointee and has affirmed comfort with the capital position. Madryn Asset Management Managing Partner Avi Amin, also a director, reaffirmed conviction in the platform. (Link)
  28. iSpecimen Inc. (NASD: ISPC) has closed a $5.0 million public offering of common stock and pre-funded warrants, with participating investors subscribing for 996,231 shares and warrants over up to 2,849,923 additional shares. iSpecimen (NASDAQ: ISPC), an online marketplace connecting biospecimen researchers with healthcare specimen providers, priced the offering on August 6 and closed August 7, 2026 for gross proceeds of approximately $5 million. The heavy pre-funded warrant component relative to common stock indicates investors managing beneficial ownership thresholds, a common structure for micro-cap issuers with concentrated demand. Proceeds are earmarked for repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, general corporate purposes and working capital. The registration statement was filed June 24, 2026 and declared effective July 30, 2026. (Link)
  29. Health Catalyst, Inc. (NASD: HCAT) has completed the sale of its Vitalware mid-revenue-cycle business to Med-Metrix LLC for $147 million in cash and used the proceeds to fully retire its credit facility. Health Catalyst (NASDAQ: HCAT) closed the divestiture of Vitalware to Med-Metrix on July 31, 2026 for $147 million of total cash consideration, subject to customary adjustments. Proceeds plus balance-sheet cash repaid and terminated all obligations under the company’s credit facility, eliminating roughly $19 million of annualised GAAP interest expense based on first-half 2026 figures. The transaction is a balance-sheet reset as much as a portfolio move: management framed the strengthened capital position as funding a narrower roadmap around cost management, clinical quality and consumer loyalty intelligence products. Med-Metrix gains coding compliance, chargemaster, charge capture and price transparency assets. (Link)
  30. Solventum Corporation (NYSE: SOLV) has reported second quarter 2026 results and announced plans to separate its Health Information Systems division, following the earlier divestiture of its Purification and Filtration business. Solventum (NYSE: SOLV) posted $2.2 billion of second quarter sales with 9.5% organic growth against 2.2% reported growth, and raised full-year guidance. The capital-structure story is the more investor-relevant one: net debt has fallen $2.6 billion since separation from 3M (NYSE: MMM) to $4.7 billion, funded largely by net proceeds from the September 2025 sale of Purification and Filtration. Management then announced its intention to spin off Health Information Systems, a second act of portfolio separation for a company itself created by spin-off. Shares rose 3.4% after hours to $90.47, surpassing the prior 52-week high. (Link)
  31. Care Options for Kids has completed the rebranding of its Chicago-area affiliate Health Force under the Care Options for Kids name, unifying its Illinois pediatric home care identity. Care Options for Kids, a national pediatric home healthcare provider, announced that Health Force has formally transitioned to the Care Options for Kids brand, establishing a single identity in Illinois. No new transaction, consideration or investor was disclosed: Health Force was already part of the platform, making this an integration and branding milestone rather than a fresh acquisition. Operating in the Chicago area since 1993, the business continues providing one-to-one pediatric care at home, in schools and in communities, with local clinicians gaining access to the platform’s shared clinical resources and standardised processes. (Link)

Venture Deals and Other

  1. Standard Capital has led a $15 million Series A in San Francisco-based Andromeda Surgical, with participation from Y Combinator, Vox Capital, Lingotto Innovation, Alumni Ventures, WestWave Capital, Pioneer Fund and Phaze Ventures. Standard Capital led the $15 million round for Andromeda Surgical, taking total funding to $30 million as the autonomous surgery company moves from clinical validation to commercial launch. Pioneer Fund has now backed the company twice, starting at seed, and Oman-based Phaze Ventures participates from its earlier investment. Investors are underwriting an endourology-first thesis: the system has performed HoLEP procedures in more than 40 patients across three countries, with enucleation times as fast as 30 minutes against a published average near 90. Andromeda holds clearance in Canada and New Zealand, with first commercial installations expected within two months. (Link)
  2. Strategic investors NDS Corporation and Aimed Bio Inc. have backed Inocras Inc.’s oversubscribed $31 million Series B-3 alongside new investors IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities and Shinhan Securities, with existing holders DSC Investment, Dunamu & Partners and InterVest participating. The oversubscribed Series B-3 takes San Diego-based Inocras to approximately $100 million of total funding. The investor syndicate is notably Korea-weighted, reflecting the company’s origins as a KAIST spinout and its installed base across Asia. Capital funds U.S. commercial and operational build-out of its CLIA/CAP-certified whole-genome sequencing and automated bioinformatics infrastructure. Investors are backing demonstrated traction rather than early-stage risk: the platform is used by more than 100 cancer institutions, supports roughly 30 South Korean hospitals and holds meaningful commercial presence in Hong Kong. Strategic participation from Aimed Bio follows a July equity investment and joint research agreement. (Link)
  3. UMass Memorial Health has led the $10 million first close of Wellinks’ Series B round, with participation from existing inside investors. UMass Memorial Health, a strategic rather than financial investor, anchored the $10 million first tranche for New Haven-based Wellinks, deepening a multiyear commercial relationship that began with a 2022 UMass Chan research collaboration and a 2024 virtual pulmonary rehabilitation partnership. The investment is underwritten by outcomes data: the joint Healthy at Home study showed participants with more than 60% lower odds of 30-day COPD readmission. Proceeds fund commercial expansion into rural and underserved markets, advance the predictive analytics engine behind the FDA-cleared Spire remote monitoring system, and extend the care model into congestive heart failure. Inside investors supported the round. (Link)
  4. Boost VC, Cleo Capital, Manna Ventures and Profluent Capital have backed SkinBit’s $6 million pre-seed round, joined by Lyft, Inc. (NASD: LYFT) co-founder Logan Green and nine board-certified dermatologists. The $6 million pre-seed for Los Angeles-based SkinBit is an unusually well-syndicated first institutional round, pairing four venture funds with an operator angel in Lyft (NASDAQ: LYFT) co-founder Logan Green, who joins the board, and nine practising dermatologists whose participation doubles as clinical distribution. Investors are funding a data-asset thesis rather than a device: proceeds deploy full-body scanners into med spas, longevity clinics and dermatology practices, targeting three locations in 2026 and fifteen by end-2027, with each scan compounding a longitudinal, patient-owned imaging record. Founded 2023 by Jonathan Benassaya, with Stanford and OHSU dermatology leadership attached. (Link)
  5. 4DMedical Limited (ASX: 4DX) has made a $3.4 million strategic investment in Seattle-based RevealDx and signed a global distribution agreement for the RevealAI-Lung nodule characterisation software. 4DMedical (ASX: 4DX) is combining a $3.4 million equity investment with exclusive distribution rights across the United States, Europe, Australia and New Zealand, a structure that gives the listed acquirer optionality on RevealDx without full consolidation. The investment follows 4DMedical’s acquisition of Austrian chest CT company contextflow, into whose platform RevealAI-Lung is already integrated and deployed at European clinical sites. The commercial case rests on reimbursement and regulatory position: FDA clearance, European MDR certification, Australian TGA approval and U.S. Medicare coverage under CPT codes 0721T and 0722T, with validation across more than 1,500 patients. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 3rd, 2026

LECO_Weekly-Healthcare-News_8-3-2026Download
  1. Lawrence, Evans & Co. Closes $30M Cross-Border Refinance and Growth Acquisition Financing for Expanding Healthcare RCM Platform Lawrence, Evans & Co. (LECO) announced the closing of a refinance and growth acquisition financing for a fast-growing healthcare revenue cycle management platform. LECO led the transaction while coordinating multiple acquisitions across several countries and managing the related overseas legal and regulatory requirements. The $30M financing supported the owner’s non-dilutive refinancing and acquisition line of credit needs, letting the company fund growth without giving up equity. Neil Johnson, Managing Partner at Lawrence, Evans & Co., LLC, led the transaction. The deal reflects LECO’s work advising healthcare and technology companies on complex, cross-border capital solutions tied to acquisition strategies. (Link)
  2. Clearview Capital agreed to exit Advantage Behavioral Health in a $610 million municipal-bond-financed sale to nonprofit QCF/I, Inc. Connecticut-based private equity firm Clearview Capital agreed to sell New Jersey-headquartered Advantage Behavioral Health, an operator of mental health centers and sober-living facilities, to nonprofit QCF/I, Inc., which is funding the purchase through a planned $610 million unrated municipal bond issuance. Clearview, together with ABH’s founders and management, is expected to receive roughly $415 million at closing, with up to $100 million more tied to performance milestones. The sale comes just over a year after Clearview recapitalized the company. ABH expects to treat more than 500,000 patients annually and generate about $170 million in revenue and $78 million of EBITDA this year. This is QCF’s fourth and largest acquisition. (Link)
  3. Blue Sea Capital closed an oversubscribed continuation vehicle for One Physics, led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard. Blue Sea Capital, a West Palm Beach private equity firm with over $1.5 billion in assets under management focused on middle-market healthcare companies valued up to $500 million, closed its first continuation vehicle to extend its partnership with One Physics. The meaningfully oversubscribed transaction was led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard, with participation from Abbott Capital and Twin Bridge Capital Partners. Both Blue Sea and One Physics management reinvested significantly. Towson, Maryland-based One Physics is North America’s leading outsourced medical physics provider, with more than 210 physicists delivering regulatory-mandated testing and compliance services to hospitals, imaging centers and cancer facilities. (Link)
  4. Kettering Health signed a non-binding letter of intent for Knox Community Hospital to join its nonprofit system. Knox Community Hospital, a 99-bed nonprofit hospital in Mount Vernon, Ohio, signed a non-binding letter of intent to join Kettering Health, a nonprofit system headquartered in Kettering, Ohio. The two Ohio organizations entered exclusive negotiations toward a definitive agreement by early fall, with closing targeted by the end of 2026 pending regulatory review. As a nonprofit combination, no purchase price applies. Kettering Health committed to significant capital investment in Knox’s service area over the 10 years after closing, including a new EHR system and workforce support. Kettering operates 14 medical centers and more than 100 outpatient locations across western Ohio; Knox would be its farthest medical center beyond southwest Ohio. (Link)
  5. Health Catalyst Capital acquired a leading Midwest provider of psychiatric medical care for elderly and disabled adults to fund regional expansion. New York-based private equity firm Health Catalyst Capital acquired a clinician-led Midwest psychiatric medical care provider serving elderly and disabled adults across long-term care facilities and hospitals. Financial terms were not disclosed, and the target remains unnamed. Both parties are private. Health Catalyst Capital invests in healthcare services and technology businesses and leverages relationships with over 250 healthcare and technology enterprises, driving value by helping portfolio companies integrate AI and build commercial relationships. With the backing, the practice plans to expand its regional footprint into additional long-term care and hospital settings, a segment seeing rising demand as the population ages. (Link)
  6. LiveWell Partners, backed by Encore Management Group, acquired Michigan Community VNA Home Health and Hospice. LiveWell Partners, a St. Louis-based home health and hospice platform backed by private equity firm Encore Management Group, acquired Detroit-based Michigan Community VNA Home Health and Hospice. Financial terms were undisclosed. Founded in 2023, LiveWell has grown largely through Midwest acquisitions and now operates across Illinois, Kansas, Michigan, Missouri and Ohio; this is its third Michigan deal. Under LiveWell’s operating model, acquired organizations keep their community identities and leadership while gaining shared clinical, operational and technology resources. Michigan Community VNA, which traces its roots to 1898, provides skilled home health, therapies, palliative care and hospice across metropolitan Detroit and complements LiveWell’s existing regional density strategy. (Link)
  7. Nexus acquired Telemetrix RPM to extend its clinical care operating system from the hospital to the home. Nexus, formerly Nexus Bedside, acquired Telemetrix RPM, a remote patient monitoring and chronic care management company operating inside native Epic workflows. Financial terms were undisclosed, and both companies are private. The deal, which closed July 23 in Cleveland, unifies inpatient coordination, remote monitoring, chronic care management and cardiac AI into a single workflow. Akram Boutros, MD, serves as CEO of both entities; former Telemetrix CEO Burley Wright becomes COO of Nexus, and founder Bret Shillingstad, MD, stays on as chief medical officer of both. The combination reflects a broader push among health tech providers toward integrated platforms connecting inpatient and post-acute care. (Link)
  8. ARC Health partnered with Old Greenwich, Connecticut-based The Waverly Group to expand collaborative pediatric care. ARC Health, a national network of mental healthcare providers, partnered with The Waverly Group, a multidisciplinary pediatric practice in Old Greenwich, Connecticut. Financial terms were undisclosed, and both organizations are private. Waverly becomes ARC Health’s second Connecticut partner and fourth in the greater New York metro area, offering ABA and behavior therapy, occupational and physical therapy, psychotherapy, psychological testing, speech therapy and related services. The practice keeps its identity and clinical leadership while gaining ARC Health’s operational resources and national provider network. CEO Vince Morra emphasized the coordinated, multidisciplinary model. ARC Health operates a provider-centric structure in which partners become equity-owning members. (Link)
  9. Included Health signed a definitive agreement to acquire Firefly Health to build a clinically integrated health plan alternative for employers. Included Health, an AI-native virtual care and navigation company, agreed to acquire Firefly Health, a clinically integrated health plan and advanced primary care provider serving more than 20,000 members through a network of over 2,300 providers. Financial terms were not disclosed, and the deal is expected to close in the third quarter of 2026 subject to regulatory review. Both companies are privately held. The combination pairs Included Health’s clinician-in-the-loop platform with Firefly’s plan design and near- and in-home network, targeting employers facing steep medical cost trends. Firefly reported 15%+ total cost of care savings and 90% member satisfaction in 2025. (Link)
  10. Graham Partners acquires TechData Service Company to form Quantive Intelligence platform Private equity firm Graham Partners acquired TechData Service Company and combined it with LLX Solutions and R Square Technology to form Quantive Intelligence, a decision-sciences platform focused on biostatistics, statistical programming, and clinical data services. The platform serves pharmaceutical and biotechnology sponsors with submission-stage clinical development support. Headquartered in King of Prussia, Pennsylvania, with operations in Massachusetts, Greater China, and India, the combined organization employs more than 700 people. Financial terms were not disclosed. The transaction closed July 1, 2026. (Link)
  11. Vital Infrastructure Property Trust acquired an EmblemHealth-leased Brooklyn medical office building for approximately $89 million. Toronto-based healthcare infrastructure REIT Vital Infrastructure Property Trust acquired the roughly 140,000-square-foot East New York Health Hub at 101 Pennsylvania Avenue in Brooklyn for about $89 million (C$126.7 million), or more than $635 per square foot, from developer Dominion Management Company. (The linked headline labels the buyer “Global Healthcare REIT,” but the acquirer is Vital Infrastructure Property Trust.) The trophy-quality building is leased long-term to nonprofit insurer EmblemHealth, with additional tenants including AdvantageCare Physicians, New York Cancer & Blood Specialists and Quest Diagnostics. CEO Zach Vaughan called it a step in Vital’s strategy to re-enter the large, fragmented U.S. healthcare real estate market. (Link)
  12. Novanta Inc. (NASD: NOVT) completed its ~$1.2 billion acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta (NASD: NOVT) completed the acquisition of Riverpoint Medical from Washington, D.C.-area private investment firm Arlington Capital Partners, paying approximately $1.2 billion in cash at closing plus a potential $250 million milestone payment due by early January 2027. Riverpoint is a category leader in minimally invasive surgical consumables, including surgical fibers for sports medicine, trauma and cardiovascular applications, with facilities in Portland, Oregon and San Jose, Costa Rica. A Novanta subsidiary borrowed $616 million under its credit facilities, funding the rest with cash on hand and a recent $300 million equity raise. The deal roughly doubles Novanta’s recurring medical consumables revenue to about $300 million. (Link)
  13. Serelora, Inc. acquired the clinical risk-stratification software of ACTIN Care Groups to extend its agentic EHR into population-level analysis. Serelora, a company building an AI-native agentic electronic health record, acquired the clinical risk-stratification software of ACTIN Care Groups. Financial terms were undisclosed, and both companies are privately held. The acquired technology includes WellCheck, a 27-instrument preventive risk battery assessing clinical, behavioral and social risk factors, which becomes a native capability of Serelora’s record. Co-founder and CTO Spencer Wozniak framed the deal as extending the system’s intelligence from the individual chart to whole populations, letting organizations identify who is trending toward risk. The acquisition moves Serelora beyond documentation into population health analytics inside the same agentic system clinicians already use. (Link)
  14. Quasar Medical acquired Medres International’s Nitinol Design and Development Center in San Diego to expand its minimally invasive device manufacturing platform. Quasar Medical, a global contract development and manufacturing organization specializing in minimally invasive devices, acquired the Medres Nitinol Design and Development Center in Carlsbad, California. Financial terms were undisclosed. The transaction covers the 10,000-square-foot facility established in 2024, its engineering talent, manufacturing capabilities and customer relationships. Both parties are private. The site becomes Quasar’s dedicated nitinol center under SVP of Technology Christine Trepanier, complementing hubs in Israel and Galway and sitting an hour from Quasar’s Tecate, Mexico production facility. Medres International retains its remaining business. The deal deepens Quasar’s exposure to nitinol, a widely used enabling material for implantable and disposable devices. (Link)
  15. Transform Health Partners completed an acquisition of Sound Surgeons to expand its platform. Transform Health Partners acquired Sound Surgeons, a bariatric and weight-loss surgery practice, along with Sound Weight & Wellness in Washington state. The deal extends the buyer’s strategy of adding medical facility assets to its portfolio, with a focus on outpatient weight-loss and bariatric services. (Link)
  16. Timshel Health, LLC added Texas-based MyMD Select to its national direct primary care holding company to open new clinics across Texas. MyMD Select, an East Texas direct primary care practice founded in 2014 by Jeremy Smith, MD, joined Timshel Health, a national holding company of direct primary care practices. Financial terms were undisclosed, and both companies are private. MyMD Select guarantees members all-hours access and same- or next-day appointments through functional-medicine-trained providers, and partners with employers to lower spending on labs, imaging and downstream care. With Timshel’s backing, MyMD Select plans to open new clinics throughout Texas. Timshel CEO Mac Findlay framed the deal as helping the practice scale while preserving its culture; Smith becomes MyMD Select’s chief medical officer. (Link)
  17. Private investor acquires Lampert’s Home Therapy A private investor acquired Lampert’s Home Therapy, Inc., a therapist-owned provider of pediatric occupational, physical, and speech therapy services based in Largo, Florida. The company serves children and adults with developmental disabilities across West Central Florida through clinic, home, school, and community settings. Founded in 2000, Lampert’s delivers specialized programs including the TheraSuit Method. Financial terms were not disclosed. The transaction closed June 22, 2026. (Link)
  18. Processa Pharmaceuticals, Inc. (NASD: PCSA) acquired Vidya Therapeutics, Inc. in a stock-for-stock transaction alongside an oversubscribed ~$200 million private placement from a syndicate led by Bain Capital Life Sciences, RA Capital Management and Janus Henderson Investors. Processa (NASD: PCSA) acquired Vidya Therapeutics, adding BTK inhibitor VT-7208, and simultaneously secured approximately $200 million in gross proceeds through Series A preferred stock priced at $1,221.19 per share. The oversubscribed placement drew Bain Capital Life Sciences, Janus Henderson Investors, RA Capital Management, SilverArc Capital, ADAR1 Capital Management, Cormorant Asset Management, Integral Health Asset Management, Marshall Wace, Octagon Capital and Soleus Capital. Proceeds fund operations into the second half of 2029 and three parallel Phase 2 programs. Existing Processa holders are left owning roughly 0.9% on a fully diluted basis, reflecting heavy dilution driven by the incoming investor syndicate. (Link)
  19. Waldencast plc (NASD: WALD) completed the sale of its Obagi Medical dermatological skincare and aesthetics business to mid-market investor Bridgepoint in a transaction valued at up to $460 million. Waldencast (NASD: WALD) closed the divestiture of Obagi Medical to Bridgepoint on July 30, 2026, in a deal valued at up to $460 million. Consideration includes roughly $366 million in cash, $30 million in vendor notes ($10 million fixed, $20 million adjustable) and up to $64 million of earnout tied to 2026 non-injectables and 2027 injectables revenue. Preliminary pro forma total consideration is about $380 million, with net cash proceeds near $334 million. Waldencast used about $178 million at closing to repay its senior term loan, eliminating $135.8 million of long-term debt. The Jersey-incorporated company now focuses on growing Milk Makeup, which generated $110.4 million of 2025 net revenue. (Link)
  20. MiMedx Group, Inc. (NASD: MDXG) agreed to acquire Sanara MedTech Inc. (NASD: SMTI) in a cash-and-stock deal valued at about $350 million. MiMedx (NASD: MDXG) entered a definitive merger agreement to acquire Sanara MedTech (NASD: SMTI) at $35 per share, a total enterprise value of approximately $350 million. Sanara holders receive $33.00 in cash plus 0.4735 MiMedx shares each, a 46% premium to Sanara’s 30-day volume-weighted average price. MiMedx will fund the cash portion with cash on hand and a committed $300 million first lien senior secured term loan from Hayfin Capital Management. The deal combines MiMedx’s surgical portfolio with Sanara’s regenerative surgical technologies, targeting 2027 combined revenue above $400 million, adjusted EBITDA margins over 20% and $20 million-plus in synergies. Closing is expected by year-end, pending Sanara shareholder and regulatory approval. (Link)
  21. Scribe Therapeutics Inc. (NASD: SCTX) closed a $155.5 million IPO at $15.00 per share, with a concurrent private placement to Sanofi. Scribe Therapeutics (NASD: SCTX) completed its IPO, selling 9,867,000 shares at $15.00, including full exercise of the underwriters’ 1,287,000-share option. Aggregate gross proceeds reached about $155.51 million, a figure that includes a concurrent private placement in which strategic partner Sanofi bought 500,000 shares at the IPO price. The shares began trading on the Nasdaq Global Market under ticker SCTX. Scribe is a clinical-stage biotech developing CRISPR-based genetic medicines, with lead candidate STX-1150 targeting PCSK9 to reduce LDL-C. The company, co-founded by Nobel laureate Jennifer Doudna, holds strategic collaborations with Sanofi and Eli Lilly. (Link)
  22. Synlogic and Caldera Therapeutics announce merger agreement and concurrent private placement Synlogic, Inc. (OTC: SYBX) and privately held Caldera Therapeutics entered a definitive all-stock merger agreement. The combined company will operate as Caldera Therapeutics and intends to list on the Nasdaq Capital Market under the ticker CALD. Concurrently, Caldera secured commitments for an approximately $278 million private placement from a syndicate of healthcare institutional investors. Proceeds are expected to fund Phase 2 trials of CLD-423, a TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease, with cash runway projected into 2029. (Link)
  23. Thoma Bravo completed its majority-stake acquisition of French occupational health software leader padoa, with existing investors Five Arrows and Kamet Ventures reinvesting. Thoma Bravo, the world’s largest software-focused investment firm with more than $172 billion in assets under management, completed its investment in padoa, the European leader in occupational health, safety and prevention software. The investment was made through Thoma Bravo’s Europe Fund, with significant participation from padoa’s co-founders and existing shareholders Five Arrows (Rothschild & Co’s alternative assets arm) and Kamet Ventures. Thoma Bravo assumes majority control while CEO Cédric Mathorel and the executive team retain a substantial stake. The capital funds AI development, customer service expansion, product innovation and international growth, particularly across the DACH region. padoa had previously raised roughly €105 million pre-buyout. (Link)
  24. PetIQ acquires MYOS muscle health portfolio PetIQ, a leading pet health and wellness company and portfolio company of Bansk Group, acquired MYOS Corp and its Fortetropin-based portfolio of muscle health products for pets. The products support muscle preservation, injury recovery, and healthy aging in companion animals. Terms of the transaction were not disclosed. The acquisition expands PetIQ’s science-backed brand portfolio and strengthens its position in the growing pet health and wellness category. (Link)
  25. Latigo Biotherapeutics files for IPO Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing non-opioid pain medicines, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 16 million shares of common stock, with an additional 2.4 million shares available to underwriters. The expected price range is $16.00 to $18.00 per share. Latigo has applied to list on the Nasdaq Global Select Market under the ticker LTGO. Its lead candidates are oral Nav1.8 inhibitors designed to stop pain transmission without addiction risk. (Link)
  26. Attovia Therapeutics files for IPO Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 12.5 million shares of common stock, with an additional 1.875 million shares available to underwriters for overallotments. The expected price range is $15.00 to $17.00 per share. Attovia has applied to list on the Nasdaq Global Market under the ticker ATTO. Proceeds will support clinical development of its ATTOBODY platform candidates. (Link)

Venture Deals and Other

  1. Function secured $450 million in non-dilutive growth financing from General Catalyst’s Customer Value Fund to scale its preventive health platform. Function, an Austin-based whole-body health company, closed $450 million in growth financing from General Catalyst’s Customer Value Fund, the firm’s non-dilutive vehicle that ties capital to customer growth rather than equity. General Catalyst manages a portfolio of 800-plus businesses. The financing follows Function’s $298 million Series B in November and its Q2 acquisitions of Getlabs’ nationwide blood-draw network and supplement platform SuppCo. Function offers 160-plus lab tests starting at $365 per year plus MRI and CT scanning across 200-plus locations, and reports 500,000-plus members. (Link)
  2. Healia, an Ohio-based healthcare benefits platform, raised a $14 million Series A led by 111° West Capital with participation from Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and Ohio-based North Coast Ventures. Healia, a Columbus, Ohio provider of a healthcare benefits platform for dual-income families and employers, raised $14 million in Series A funding led by 111° West Capital, bringing total funding to $18 million. Participating investors included Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and North Coast Ventures, a Cleveland, Ohio venture firm. Led by founder and CEO Priyang Shah, Healia builds health reimbursement arrangements that let employers cover employee healthcare costs and premiums when workers enroll in a spouse’s plan. Its platform compares plan options on total cost of ownership, facilitates spousal-plan enrollment and automates claims to reimburse expenses within hours. Proceeds fund operations and product development. (Link)
  3. Flourish Health raised $46 million, with a $26 million Series A led by B Capital, F-Prime and Cherryrock Capital, to scale intensive youth mental health care. Flourish Health, a Richmond, Virginia mental health provider for young people with serious, complex needs, announced $26 million in Series A funding led by B Capital, F-Prime and Cherryrock Capital, which combined with $20 million in previously undisclosed funding brings total capital raised to $46 million. The Series A investors are backing a psychiatrist-led, in-home model delivered through four-person Care Pods and a proprietary AI workflow platform. Studies with major health plans showed 70–96% reductions in hospitalizations and 69–90% reductions in residential treatment. The new capital funds national expansion in partnership with large health plans, platform investment and clinician hiring. (Link)
  4. Doctronic acquired pediatric telehealth company Summer Health, building on its $40 million Series B round backed capital base. Doctronic, an AI-enabled doctor consultation platform, acquired Summer Health, a text-based pediatric telehealth company, to extend primary care to children from birth. Deal terms were undisclosed; both companies are private. Doctronic raised $40 million in Series B funding in March, bringing total funding to $65 million, part of which was earmarked for pediatric expansion. Summer Health, founded in 2022, had raised $11.65 million in Series A funding in 2024 after an earlier $7.5 million round, and has supported more than 100,000 pediatric encounters. Doctronic plans to use Summer Health’s repository of 100,000-plus pediatric conversations to develop pediatric-specific AI models; founder Ellen DaSilva joins to lead B2B growth. (Link)
  5. Epitel, Inc. secured a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures to expand its wireless remote EEG monitoring system. Epitel, a Salt Lake City AI-driven wireless brain health company, closed a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures, with new and existing investors participating. The capital funds commercial expansion of its REMI Remote EEG Monitoring System, a fully wireless FDA-cleared platform that pairs wearable sensors with AI-driven seizure detection for at-home monitoring over several weeks. The REMI portfolio holds five FDA 510(k) clearances and is cleared for patients as young as one year old. Proceeds scale sales, marketing and customer teams, streamline provider deployment and grow ambulatory market access. Joshua Phillips of Catalyst Health Ventures chairs Epitel’s board. (Link)
  6. Dopl Technologies raised a $6.3 million seed round led by SpringTide Ventures, with participation from WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures and Precursor Ventures. Dopl Technologies, a Bothell, Washington medical technology company developing a robotic ultrasound platform, raised $6.3 million in seed funding led by SpringTide Ventures, bringing total funding above $8 million. WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures, Precursor Ventures and others participated. Led by CEO and co-founder Ryan James, PhD, Dopl combines robotics, AI and remote clinical expertise across its Traverse robotic ultrasound system, Dopl Connect data platform and SonoFlex distributed sonographer workforce tool. The company currently serves critical access hospitals across Washington State. Proceeds fund FDA clearance work, including product verification and validation, submission activities, clinical evaluation and initial market release. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Lawrence Evans & Co is pleased to announce the successful closing of a $30M Refinance / Growth Capital facility for a Healthcare Revenue Cycle Management (RCM) Platform

Lawrence, Evans & Co., LLC is pleased to announce the successful closing of a refinance and growth acquisition financing for a rapidly expanding healthcare revenue cycle management (RCM) platform.

LECO successfully led the transaction while simultaneously navigating multiple acquisitions across several countries—and the associated overseas legal and regulatory requirements—to support the owner’s non-dilutive refinancing and acquisition line of credit needs.

The transaction was led by Neil Johnson, Managing Partner at Lawrence, Evans & Co., LLC.

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 27th, 2026

LECO_Weekly-Healthcare-News_7-27-2026Download
  1. Longshore Capital Partners entered a strategic growth partnership with revenue cycle management provider Prochant. Chicago-based Longshore Capital Partners, a lower middle-market private equity firm that takes control positions in North American services businesses with $5 million to $15 million of EBITDA, invested in Prochant, a Charlotte, North Carolina technology-enabled RCM provider serving home medical equipment, DME, infusion and specialty pharmacy operators. Terms were undisclosed. Capital will fund technology, analytics, AI and automation investment, service capacity expansion, new revenue cycle product development and talent acquisition, alongside acquisitions in core markets. Longshore is backing an existing management team under CEO Joey Graham, preserving leadership and culture while accelerating investment in a recurring-revenue outsourced services model. (Link)
  2. SkyKnight Capital, L.P. agreed to acquire a controlling position in Apex Infusion from FFL Partners, which retains a minority stake alongside the clinician-led management team. SkyKnight Capital, a San Francisco private equity firm, signed a definitive agreement to partner with Apex Infusion, a Signal Hill, California omnichannel infusion services provider founded in 2006. FFL Partners, which completed its investment in 2024, remains a minority shareholder, and Apex’s clinician-led management retains significant ownership and continues to lead the business. Apex delivers therapy through a home infusion nursing network and roughly 40 ambulatory infusion suites. SkyKnight intends to fund new market entry, health system and payor partnerships, and technology-enabled access initiatives across a site-of-care shift thesis. (Link)
  3. Winterbird Partners made a growth investment in Minneapolis-based Microsoft services partner Emergent Software. Winterbird Partners invested in Emergent Software, a Minneapolis, Minnesota Microsoft services partner specializing in data modernization, AI deployment, cloud transformation, application development and managed services. Deal value was not disclosed. Led by CEO Jamie Anderson, Emergent manages solutions across the Microsoft ecosystem including Fabric, Azure, Copilot, Foundry and modern data platforms. Proceeds will fund headcount expansion, additional service capabilities and entry into new geographies. For Winterbird, the transaction is a bet on the durability of enterprise AI and data-platform implementation, backing a founder-led services firm against a single hyperscaler ecosystem rather than horizontal consultancy model. (Link)
  4. Healthcare technology platform Focus entered a definitive agreement to acquire Plano, Texas-based managed technology services company GuideIT. Focus, a Chicago-headquartered healthcare technology services company, agreed to acquire GuideIT, a nationally recognized managed technology services provider offering managed IT, cybersecurity, cloud integration, IT and clinical service desk, and medical data services. Terms were undisclosed; GuideIT will operate as GuideIT, A Focus Company. Focus supports more than 100 electronic health record and practice management systems and is consolidating fragmented healthcare vendor relationships into a single accountable partner. GuideIT CEO and board member Russell Freeman described a deliberate partner selection process. The acquisition scales Focus’s Unified Healthcare Platform thesis through capability breadth rather than geographic density. (Link)
  5. Knox Lane completed its $437 million take-private acquisition of Cross Country Healthcare, Inc. (formerly NASD: CCRN), concurrently selling the locums division to portfolio company All Star Healthcare Solutions. Growth-oriented investment firm Knox Lane closed its all-cash acquisition of Cross Country Healthcare at $13.25 per share, valuing the technology-enabled workforce solutions company at roughly $437 million and ending its NASD listing. The deal follows a terminated agreement with Aya Healthcare. Knox Lane simultaneously moved Cross Country’s locum tenens division into All Star Healthcare Solutions, an existing portfolio company, creating immediate platform consolidation. Managing Partner John Bailey and Partner Shamik Patel cited the company’s position at the intersection of workforce services and technology. Joel Tremblay, formerly of Medical Solutions, was installed as CEO, succeeding co-founder Kevin Clark. (Link)
  6. Care Career acquired MAS Medical Staffing, completing its first acquisition phase and lifting consolidated annual revenue beyond $150 million. Woodbridge, New Jersey-based Care Career, a healthcare workforce technology organization led by CEO Siva Konatham, acquired Manchester, New Hampshire-based MAS Medical Staffing, including its travel, allied and per diem operations and technology assets. Financial terms were undisclosed. This is Care Career’s seventh acquisition in 24 months, following IDR Healthcare in February 2026, Source Medical Staffing in October 2025, and four firms in May 2025. The completed first round now exceeds $150 million of annual revenue, with signed LOIs expected to close in Q3 2026 pushing consolidated revenue past a quarter billion by year-end, aided by MAS’s Maestra workforce platform. (Link)
  7. Equality Asset Management-backed Mindoula acquired Valera Health and Janus Healthcare Partners in a double transaction expanding its whole-person care enablement platform. Mindoula, the Silver Spring, Maryland behavioral health company backed by Equality Asset Management, simultaneously acquired New York-based virtual mental health provider Valera Health and Duxbury, Massachusetts psychiatric collaborative care provider Janus Healthcare Partners. Terms were undisclosed. These are Mindoula’s third and fourth acquisitions since its 2013 founding, following Care at Hand and 180 Health Partners. Valera contributes more than 300 multi-state behavioral providers and specialization in suicide risk reduction, DBT and serious mental illness; Valera had itself raised $74.3 million and acquired Vita Health in 2025. Janus adds psychiatry CoCM capability, positioning Mindoula for value-based contracts with payers and health systems. (Link)
  8. Beacon Behavioral Partners entered Ohio and Michigan through a partnership with Ohio- and Michigan-based Pure Psychiatry, adding a 17-location outpatient platform. Plano, Texas-based Beacon Behavioral Partners, a growing network of independent psychiatric practices, acquired Pure Psychiatry, establishing its first presence in Ohio and Michigan and marking one of its largest expansions to date. Financial terms were undisclosed. Pure Psychiatry, led by founders Taylor Hennrick, PA-C, Sarang Patel, PA-C and Dr. Rakesh Amin, provides psychiatric care across all age groups including medication management for anxiety, depression, ADHD and bipolar disorder. Beacon will supply operational, administrative and strategic support to fund de novo clinic openings and provider recruitment. The deal follows Beacon’s appointment of Rob Jardeleza as CEO roughly a week earlier. (Link)
  9. Truehelm-backed Wildflower Health acquired digital pelvic floor platform Every Mother, marking its entry into direct-to-consumer women’s health. Wildflower Health, the San Francisco tech-enabled women’s health company backed by Truehelm, acquired Every Mother, a clinically validated core and pelvic floor therapy platform founded by Allison Rapaport. Terms were undisclosed. Wildflower operates enterprise infrastructure connecting commercial health plans, risk-bearing provider groups and patients across all 50 states, supporting thousands of women’s health providers. Every Mother contributes HSA/FSA-eligible on-demand exercise programs addressing diastasis recti, urinary incontinence, pelvic organ prolapse and pelvic pain. Strategically, the acquisition adds a consumer subscription revenue channel to an enterprise contracting model and extends patient relationships beyond the traditional six-to-twelve-week postpartum drop-off. (Link)
  10. DuneGlass Capital-backed Aviva Aesthetics expanded into Ohio through a partnership with Avon, Ohio-based Vitality Health. Aviva Aesthetics, the Chicago-based entrepreneur-owned medical aesthetics platform launched in 2024 with healthcare services independent sponsor DuneGlass Capital, partnered with Vitality Health, a medical aesthetics and wellness practice in Avon, Ohio founded in 2014 by Alana Mercer, PA-C. Terms were undisclosed. This is Aviva’s eighth partnership of 2026 and its first Ohio location, deepening Midwest presence. Vitality Health provides injectables, laser treatments, skin rejuvenation, weight management and hormone optimization. Aviva’s Entrepreneur Equity structure explicitly positions against traditional private equity roll-ups, allowing founders to retain full equity and control while accessing scale economics and back-office support. (Link)
  11. PE-backed Premier Care Dental Management acquired cosmetic dentistry practice Brookline Smile Artists in Massachusetts. Premier Care Dental Management, the New Hyde Park, New York dental clinical organization operating under the Dental365 brand and backed by The Jordan Company, added Brookline, Massachusetts-based Brookline Smile Artists to its network. Terms were undisclosed. PCDM supports practices across New York, Connecticut, New Jersey, Pennsylvania, Ohio, New Hampshire, Massachusetts and Rhode Island, and has pursued an acquisition-led growth cadence including multiple Ohio additions earlier in 2026. The tuck-in extends the sponsor-backed platform further into higher-margin cosmetic dentistry, a service line with meaningful cash-pay mix, while continuing the roll-up strategy aimed at retiring and scaling-back owner-dentists across the Northeast. (Link)
  12. Shore Capital Partners-backed Innovate 32 partnered with Houston-based Post Oak Dental, expanding its Texas dental support organization footprint. Innovate 32, the Nashville-based dental services organization formed by Chicago lower middle-market private equity firm Shore Capital Partners, closed a partnership with Post Oak Dental, an established Houston, Texas practice. Terms were undisclosed. Under CEO Josh Johnson and a board combining dentists, multi-site healthcare operators and private equity executives, Innovate 32 has assembled a network across Texas, Tennessee, Florida and the Mid-Atlantic since its 2024 founding. Post Oak Dental retains its clinical focus while gaining management infrastructure. For Shore, the affiliation continues a disciplined buy-and-build in general dentistry, prioritizing clinician alignment and local leadership over transactional roll-up. (Link)
  13. Dentalcorp entered the U.S. market with the acquisition of Florida-based Northstar Dental Partners. Toronto-based Dentalcorp, one of the largest dental support organizations in North America, acquired Northstar Dental Partners, a Boca Raton-headquartered group supporting 21 dental practices across South Florida, the Treasure Coast, Southwest Florida and Central Florida. Founder and CEO Dr. Jordan Tomalty retains an ownership stake and will remain instrumental to continued growth. Combined with Dentalcorp’s Canadian network, the partnership brings the total to over 650 supported practices. (Link)
  14. vybe urgent care acquired Liberty Urgent Care’s Horsham and Hatfield centers, supported by growth-oriented debt financing from Live Oak Bank. vybe urgent care, the leading independent urgent care operator in greater Philadelphia, acquired Liberty Urgent Care’s two Montgomery County, Pennsylvania centers, expanding its network from 16 to 18 sites. Terms were undisclosed. The transaction was funded through a recent growth-oriented refinancing completed with Live Oak Bank, which vybe intends to draw on for further acquisitions and de novo development. Liberty founder Erik Soiferman, D.O. joins as Vice President of Occupational Medicine Services, strengthening vybe’s occupational health and workers’ compensation capabilities. The debt-funded structure allows the independent operator to consolidate a fragmented regional market without an equity sponsor. (Link)
  15. Ares Management Corporation (NYSE: ARES) and Rubicon Founders-backed US Heart & Vascular acquired Tennessee physician-owned practice Apex Vascular and its outpatient center. US Heart & Vascular, the Nashville-area cardiovascular support services platform backed by funds managed by the Private Equity Group of Ares Management (NYSE: ARES) alongside Rubicon Founders, acquired Apex Vascular and Apex Vascular Outpatient Center. Terms were undisclosed. Headquartered in Lenoir City, Tennessee, Apex has served East Tennessee for nearly two decades across Knoxville, Crossville, Harrogate, Decatur, Sevierville and Oak Ridge, treating peripheral artery disease, varicose veins, carotid artery disease and dialysis access. Founder Christopher Pollock, MD cited access to resources for regional expansion. The tuck-in deepens USHV’s density in a specialty prized for recurring outpatient procedure volume. (Link)
  16. Paradigm Oral Health bought back BlackRock, Inc.’s (NYSE: BLK) Long Term Private Capital stake in a surgeon-led transaction backed by a Warburg Pincus-led group including Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Lincoln, Nebraska-based Paradigm Oral Health repurchased BlackRock Long Term Private Capital’s ownership stake, returning majority control to its surgeons and management. The buyback is funded by a significant investment led by Warburg Pincus, a private partnership since 1966, in partnership with Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Terms were undisclosed. Founded in 2018 by David Rallis, DDS, MD, Paradigm operates an oral surgery and digital dentistry platform built to attract and retain surgeons. The structure is notable for reversing conventional sponsor control: incoming capital supports clinician majority ownership, technology investment, advanced training and de novo clinic expansion. (Link)
  17. Groups Recover Together acquired Better Life Partners in its first-ever acquisition, doubling its New England patient volume.Burlington, Massachusetts-based Groups Recover Together, the value-based opioid use disorder treatment provider backed by Oak HC/FT, Bessemer Venture Partners, Transformation Capital, RRE Ventures, Optum Ventures and Kaiser Permanente Ventures, acquired Better Life Partners in a transaction that closed March 31. Financial terms were undisclosed. Better Life Partners, founded in Vermont in 2018 and backed by aMoon, Alumni Ventures, F-Prime Capital, Maverick Ventures and .406 Ventures, had raised $26.5 million in a 2023 Series B but experienced financial distress. CEO Cooper Zelnick highlighted mental health and virtual primary care capabilities the company intends to scale nationally beyond New England. (Link)
  18. Ohio-based Cardinal Health (NYSE: CAH) agreed to acquire the Diabetes Health business of AdaptHealth Corp. (NASD: AHCO) and, in its entirety, NMS Capital-backed Strive Medical for approximately $360 million in cash. Cardinal Health (NYSE: CAH), headquartered in Dublin, Ohio, deployed roughly $360 million of cash across two definitive agreements to scale its at-Home Solutions platform, subject to working capital adjustments. The AdaptHealth (NASD: AHCO) unit serves over 225,000 patients annually through a centralized mail-order CGM model, while NMS Capital portfolio company Strive Medical adds urology, wound care, ostomy and incontinence supply distribution to 20,000-plus patients. Both transactions build on Cardinal’s Advanced lDiabetes Supply acquisition and are expected to be accretive to non-GAAP EPS within twelve months of close, extending the Ohio distributor’s consolidation of fragmented direct-to-patient supply channels. (Link)
  19. Surgery Partners, Inc. (NASD: SGRY) agreed to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $795 million. Surgery Partners (NASD: SGRY), the Brentwood, Tennessee short-stay surgical facility operator, placed into escrow signature pages to sell its Idaho Falls hospital interests to existing partner Intermountain Health, a Utah-based nonprofit system of 34 hospitals and roughly 400 clinics. The transaction values the combined facilities at approximately $1.15 billion, with total consideration to Surgery Partners of about $795 million before purchase price adjustments. Physician ownership of Mountain View Hospital is unchanged. CEO Eric Evans framed the divestiture as portfolio optimization, refocusing capital toward ambulatory surgery centers. The company reaffirmed 2026 revenue guidance of $3.35–$3.45 billion excluding transaction impact. (Link)
  20. Gentherm Incorporated (NASD: THRM) acquired Ohio-based Innovative Medical Equipment, LLC, maker of the ThermaZone thermal therapy device. Gentherm (NASD: THRM), the Novi, Michigan thermal management and pneumatic comfort technology leader, acquired Innovative Medical Equipment, a Cleveland-area, Ohio provider of the ThermaZone non-opioid hot-and-cold thermal therapy system. Terms were undisclosed. Founder and President Brad Pulver framed Gentherm’s scale and global operating footprint as the growth enabler for the Ohio business. Management expects revenue synergies from cross-selling ThermaZone through Gentherm’s expanded healthcare customer channels. Announced alongside record Q2 2026 revenue of $416 million, raised full-year guidance and a new $400 million repurchase authorization, the deal advances Gentherm’s strategic pivot toward higher-margin medical adjacencies. (Link)
  21. RS2 Healthcare Partners, the Boston-based private equity firm formerly known as Riverside Partners, completed an investment in KMM Group, a Hatboro, Pennsylvania-based vertically integrated precision contract manufacturer serving the medical device industry. RS2 Healthcare Partners, founded in 1989 and rebranded from Riverside Partners in May 2026 to formalize an exclusive lower-middle-market healthcare strategy, closed an investment in KMM Group. Terms and stake size were undisclosed. The firm has raised $1.6 billion in total capital commitments since inception and concentrates on pharma services, medical device contract manufacturing and technology-enabled healthcare, supported by healthcare, clinical and AI advisory boards. KMM produces complex, tight-tolerance components for failure-intolerant end markets. J. Mark King joins as President and CEO, while co-founders John Shegda and Eric Wilhelm move to Chief Technology Officer and Executive Vice President, Business Transformation, preserving customer and employee continuity under sponsor ownership. (Link)
  22. Eurofins Scientific (EUFI.PA) agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America for an enterprise value of $400 million. Eurofins Scientific, a global leader in bioanalytical testing, reached agreement with Element Materials Technology to acquire its North America Life Sciences Testing Services business, encompassing biopharma product testing, environmental testing and food testing across a network of 27 laboratories and facilities employing approximately 750 FTEs. The business is expected to generate over $150 million in 2026 revenues with profitability in line with the Eurofins Group average. The transaction expands Eurofins’ geographic footprint in key U.S. and Canadian regions where it has been underrepresented and is expected to close in Q4 2026 subject to customary regulatory approvals. (Link)
  23. Repligen Corporation (NASD: RGEN) agreed to acquire BioLife Solutions, Inc. (NASD: BLFS) for a total enterprise value of approximately $1.5 billion. Repligen will acquire BioLife in a cash-and-stock transaction valued at $31.00 per BioLife share ($11.25 cash plus 0.1442 shares of Repligen common stock), representing a 24% premium to the 90-day VWAP. The deal adds BioLife’s market-leading biopreservation media platform (including CryoStor) and cell-processing tools that support 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials. The transaction is expected to be accretive to growth, margins and adjusted EPS (at least 5 cents in year one and 25 cents in year two) with $20–30 million of synergies; closing is targeted for Q4 2026. (Link)
  24. Nordic Capital agreed to sell life sciences software platform ArisGlobal to Dassault Systèmes (Euronext Paris: DSY) for up to $2 billion, marking a full exit for the Swedish sponsor. Nordic Capital, which manages approximately €39 billion, is exiting ArisGlobal entirely in a sale to Dassault Systèmes (Euronext Paris: DSY) reported at $1.8 billion cash plus a $200 million earnout. Nordic first invested in 2019 via its ninth fund at a reported $700 million enterprise value and added to its stake in 2021. Under Nordic’s ownership the Waltham, Massachusetts company converted to SaaS, completed two bolt-ons and is expected to generate roughly $175 million of 2026 revenue, processing 12 million safety cases annually for 200-plus customers. Closing is expected in the second half of 2026. (Link)
  25. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail assets of The Cannabist Company Holdings Inc. across five markets for up to $35 million. Vireo Growth, through subsidiary Vireo Health of Arcadia, agreed to acquire selected operations from Cannabist subsidiaries in Colorado, Illinois, Massachusetts, New Jersey and West Virginia for total consideration of up to US$35 million (up to US$18.75 million cash at closing plus up to US$16.25 million in seller notes), subject to adjustments and regulatory approvals. The staged transaction is expected to add up to 25 dispensaries plus cultivation and production assets, deepening Vireo’s Colorado presence and adding four new states. Closing is targeted through 2026 into 2027 amid Cannabist’s CCAA and Chapter 15 proceedings. (Link)
  26. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) agreed to acquire Planet 13 Holdings Inc. (CSE: PLTH; OTCQX: PLNH) in an all-share merger. Vireo Growth entered a definitive merger agreement to acquire all outstanding equity of Planet 13, with each Planet 13 share converting into 0.015383618 of a Vireo subordinate voting share (16.6% premium to the 20-day VWAP and 24% premium to the closing price as of July 24, 2026). The transaction deepens Vireo’s Nevada and Florida footprints (adding the flagship Las Vegas superstore, additional dispensaries, cultivation/production capacity and licenses) and adds a Waukegan, Illinois dispensary. On a pro forma basis with prior announced deals, Vireo expects to operate approximately 265 dispensaries across 15 states. Closing is subject to stockholder, regulatory and listing approvals. (Link)
  27. First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) and Westin Acquisition Corp. (NASD: WSTN) announced a definitive business combination agreement to create a publicly traded healthcare and wellness company. The transaction values First Choice at a pro forma enterprise value of approximately $650 million and is expected to accelerate its strategic rebrand to Wellgevity 360, a platform focused on longevity, preventative care and personalized biology-driven solutions. Westin will domesticate and the combined company is expected to trade on NASD. Closing is targeted for Q4 2026 subject to customary approvals and conditions. (Link)
  28. Avanos Medical, Inc. (NYSE: AVNS) stockholders approved the company’s $25.00-per-share take-private by American Industrial Partners, valuing the medtech at roughly $1.272 billion. Avanos Medical (NYSE: AVNS) shareholders voted overwhelmingly in favor of the acquisition by affiliates of funds advised by American Industrial Partners, with approximately 99.75% of shares voted supporting the merger, representing about 74.96% of shares outstanding as of the June 18 record date. Holders receive $25.00 per share in cash, an enterprise value near $1.272 billion and a 72.1% premium to the pre-announcement close, plus an 82.8% premium to the 30-day VWAP. All regulatory approvals had been obtained, with closing expected no later than July 27, 2026. The operationally focused industrials investor takes Avanos private, delisting from the NYSE. (Link)
  29. Royalty Pharma plc (NASD: RPRX) acquired a portion of Neurimmune’s royalty interest in cliramitug for up to $425 million. Royalty Pharma (NASD: RPRX) committed up to $425 million to Zurich-based Neurimmune in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug, an investigational anti-amyloid antibody for ATTR cardiomyopathy. The structure front-loads $125 million upfront, with a further $125 million payable in Q1 2027 and $175 million tied to clinical and regulatory milestones. Cliramitug is licensed globally to Alexion, AstraZeneca Rare Disease, which is running the Phase 3 DepleTTR-CM trial. For Royalty Pharma, the transaction buys exposure to the rapidly growing ATTR-CM market; for Neurimmune, it is non-dilutive capital funding its internal pipeline. (Link)
  30. Aurobindo Pharma Limited (NSE: AUROPHARMA; BSE: 524804), through wholly owned subsidiary Apitoria Pharma Private Limited, agreed to acquire 80% ownership control of A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA at a $17 million enterprise value. Aurobindo Pharma (NSE: AUROPHARMA; BSE: 524804) is deploying $13.6 million in cash through Apitoria Pharma for an 80% interest in A1 Biochem Group’s contract research business, struck at a $17 million enterprise value on a debt-free, cash-free basis, subject to closing adjustments. The existing promoter retains 20%, and A1 Biochem Labs (India) will absorb A1 Biochem Labs LLC and the CRO business of A1 Biochem Research (India). The target posted FY26 turnover of ₹1,024.42 million and EBITDA of ₹465.46 million — a 45% margin — across Wilmington and Hyderabad labs with 90-plus scientists. Aurobindo is building an integrated CRDMO platform across the API value chain; closing is expected in 90 to 120 days. (Link)
  31. Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (NASD: NEUP) announced an all-share merger agreement and associated financing. Scancell will acquire Neuphoria in an all-share transaction; the combined company will operate as Scancell, list on NASD (in addition to AIM) and advance a pipeline of targeted, off-the-shelf active immunotherapies, led by iSCIB1+ in advanced melanoma. Existing Scancell shareholders are expected to own approximately 85.5% and Neuphoria shareholders 14.5% on a pro forma basis (before financing). Concurrent financing of up to $89 million (equity and debt) is intended to fund the global registrational Phase 3 trial. Closing is targeted for late Q4 2026 subject to shareholder and regulatory approvals. (Link)
  32. Footbridge Partners and ALZA Capital Partners sold Ohio-, Pennsylvania- and Michigan-based medical spa platform The Skin Center to an undisclosed middle-market healthcare private equity fund. Footbridge Partners and ALZA Capital Partners exited The Skin Center, a medical spa and cosmetic surgery platform operating 14 locations across Pennsylvania, Ohio and Michigan, selling to an unnamed middle-market healthcare private equity fund in a recapitalization. Terms were undisclosed. Founded in 1981 by Jerry and Dominic Brandy, the company delivers neurotoxins, dermal fillers, laser skin resurfacing, laser hair removal and cosmetic surgery under CEO Eric Warden. Footbridge co-founder and Managing Partner David Rosner credited management and providers for the outcome. The incoming sponsor inherits a platform positioned for de novo openings and further M&A across the consolidating medical aesthetics market. (Link)

Venture Deals and Other

  1. MannKind Corporation (NASD: MNKD) raised approximately $50 million in a private placement led by Frazier Life Sciences. MannKind (NASD: MNKD) closed a roughly $50 million private placement with institutional investors, led by longstanding biotech investor Frazier Life Sciences. The company sold 10,440,838 common shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, with a $0.01 exercise price and no expiry. Proceeds fund general corporate purposes including a $45 million contingent value rights payment triggered by the FDA’s July 23, 2026 approval of Furoscix ReadyFlow for edema in heart failure and chronic kidney disease patients. (Link)
  2. Insight Partners led a $19 million Series A in AI-native provider credentialing platform Assured, with participation from First Round Capital and Kindred Ventures. Insight Partners led Assured’s $19 million Series A, joined by existing backers First Round Capital and Kindred Ventures, bringing total capital raised to $25 million following a $6 million seed in September 2025. Insight Managing Director Teddie Wardi articulated the thesis directly: incumbent credentialing tools function as systems of record while Assured’s agents perform the work itself, verifying data against more than 2,000 primary sources and cutting credentialing time by 30%. Launched in 2024, the NCQA-certified CVO serves over 100 organizations including Houston Methodist. Proceeds expand R&D and go-to-market teams ahead of a privileging product in early 2027. (Link)
  3. Brevy Care raised $4.77 million with participation from GreyMatter Capital to expand Medicaid reimbursement software for family caregivers. Brevy Care, a developer of software helping family caregivers access Medicaid reimbursements, raised $4.77 million in a round including San Francisco-based GreyMatter Capital, a mental and behavioral health-focused venture firm founded in 2021 that typically writes first checks of $250,000 to $1.2 million. The financing brings Brevy’s total capital raised to $4.92 million. GreyMatter’s thesis centers on early-stage innovation in behavioral healthcare delivery and adjacent care-navigation infrastructure. For investors, Brevy addresses a reimbursement-access gap in self-directed Medicaid programs, a payer-funded and demographically supported category as aging populations shift care burden toward unpaid family members. (Link)
  4. Sixth Street Growth led a $120 million Series D in autonomous revenue cycle management platform Candid Health, with participation from Oak HC/FT, 8VC and Y Combinator. Candid Health raised $120 million led by Sixth Street Growth, the dedicated growth platform of Sixth Street, which manages over $135 billion and has invested more than $13 billion across 90-plus companies. Oak HC/FT, 8VC and Y Combinator participated. The round marks a 3x valuation increase over the February 2025 Series C led by Oak HC/FT. Managing Director Alex Katz cited diligence calls with nearly 40 customers and proof points applying agentic AI at scale. Candid reported 190% year-over-year annual contracted run-rate growth and 180% net dollar retention in 2025, targeting the $280 billion US RCM spend. (Link)
  5. Innovation Endeavors and Xora co-led a $21 million Series A in sensor developer Elio, with participation from Kevin Weil, Scribble VC, UpWest and Resolute Ventures. Elio, a Silicon Valley and Israel-based company building sensors designed for artificial intelligence rather than human vision, raised $21 million co-led by Innovation Endeavors and Xora. Kevin Weil and Scribble VC participated, alongside existing investors UpWest and Resolute Ventures, who led the prior round. Total funding reaches $29 million. Founded by former Meta AR/VR executives, Elio embeds computation directly into optics using dynamic micromirror layers that behave like a neural network, letting AI decide what to capture in real time. Investors are backing applications spanning microscopy, semiconductor inspection, robotics and defense drone detection. (Link)
  6. 7wire Ventures and Allumia Ventures co-led an oversubscribed $16.2 million Series A in Karoo Health, joined by First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels. Karoo Health, an Albuquerque, New Mexico cardiovascular technology company led by CEO Ian Koons, closed a $16.2 million oversubscribed Series A co-led by 7wire Ventures and Allumia Ventures, with First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels participating. Managing Partners Lee Shapiro of 7wire and Jeff Stolte of Allumia join the board. Deployed programs have produced independently analyzed reductions exceeding 40% in emergency department visits and inpatient admissions, plus a greater than 10% total cost of care reduction. Karoo supports 600-plus cardiology providers across 11 states; proceeds fund predictive models and health plan expansion. (Link)
  7. FUSE led a $16 million financing in AI-powered concierge primary care platform Prosper Medical, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and WTI. Prosper Medical, a San Francisco company founded in 2026 by CEO Ryan McQuaid and CMO James Wantuck, MD, raised $16 million led by FUSE alongside Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and Western Technology Investment. Investors are backing repeat founders who previously built PlushCare and sold it to Accolade for $450 million. Unlike cash-pay concierge peers, Prosper is in-network with major insurance plans across all 50 states at a $69 monthly membership, using an AI care layer for longitudinal data aggregation and referral coordination. Proceeds expand the physician network and enter new markets. (Link)
  8. Decathlon Capital Partners provided a non-dilutive growth-debt investment to value-based care technology company Health Endeavors. Decathlon Capital Partners, a growth-debt provider with offices in Palo Alto and Park City, made a strategic investment in Health Endeavors, a Farmington, Utah technology partner to Accountable Care Organizations. Deal size was undisclosed, but the structure requires no dilution of existing shareholders. Managing Director Matt Hoffman framed the investment as conviction in value-based care economics. Health Endeavors serves over 2 million patients with 16-plus years of ACO experience and partnerships with Novant Health and Providence. Decathlon targets companies with $4 million to $100 million revenue, 10%-plus growth and near-term visibility to cash-flow-positive status, avoiding equity dilution and loss of control. (Link)
  9. Vensana Capital and Ohio-based Mutual Capital Partners co-led a $30 million Series A in TYBR Health, with participation from Neovate Capital Partners and existing investors. TYBR Health, a Houston, Texas orthopedic biologics company co-founded and led by CEO Tim Keane, PhD, raised $30 million in Series A financing co-led by Vensana Capital and Mutual Capital Partners, the Cleveland, Ohio venture firm managed by Bill Trainor and Wayne Wallace that invests exclusively in Midwest healthcare IT and medical device companies. Proceeds expand commercial access to the FDA-cleared B3 GEL System, a flowable extracellular matrix hydrogel, broaden indications and fund clinical studies on tissue protection during orthopedic surgery. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 20th, 2026

LECO_Weekly-Healthcare-News_7-20-2026Download

Healthcare Weekly News and Deals – 20 July, 2026

  1. PE-backed Ridgemont Equity Partners and Coogee Bay Partners Acquire Ohio-based Caring Transitions. Ridgemont Equity Partners, a Charlotte-based middle-market private equity firm, and Coogee Bay Partners (digital-marketplace operators Joshua Ellstein and Michael Felman) acquired Caring Transitions, a Cincinnati, Ohio-based nationwide franchise network providing senior move management, downsizing, estate-sale and home-cleanout services through its CTBids digital marketplace. Terms were undisclosed. Ellstein and Felman become Co-Executive Chairmen alongside President Joe Lewandowski. Founded in 2006, the Ohio company operates more than 300 franchise locations. The sponsors plan to scale and modernize the CTBids platform to capture liquidity from an aging population downsizing its households, blending Ridgemont’s buyout capital with Coogee Bay’s marketplace-operating expertise. (Link)
  2. Great Point Partners-backed VetnCare acquired Holistic Veterinary Care. VetnCare, a Northern California veterinary hospital group backed by Greenwich-based healthcare private equity firm Great Point Partners, acquired Holistic Veterinary Care, an Oakland practice specializing in integrative and rehabilitative animal medicine founded in 2009. Terms were undisclosed. The deal is VetnCare’s sixth add-on since Great Point’s investment and the first under CEO Matt Kirchner; founder Dr. Gary Richter stays on as Clinical Director. Great Point Partners, founded in 2003 with roughly 30 professionals, backs a buy-and-build strategy that has more than doubled VetnCare over three years while preserving local clinical leadership. The tuck-in extends the platform into alternative and rehabilitative care rather than simply adding locations. (Link)
  3. HCAP Partners / Hamilton Lane (Nasdaq: HLNE)-backed PAX Health acquired independent medical examination provider MAKRAF IME. PAX Health, a behavioral health company backed by HCAP Partners and funds managed by Hamilton Lane (Nasdaq: HLNE), acquired MAKRAF IME, a New Jersey statewide psychology and neuropsychology independent medical examination group serving 17 counties. Terms were undisclosed. The deal is PAX Health’s fourth acquisition since its March 2024 founding and expands its medical-legal evaluation platform for insurers, employers, attorneys and state agencies. MAKRAF’s licensed examiners deliver opinions on causality, permanency and fitness-for-duty. For its sponsors, the tuck-in advances a buy-and-build strategy in behavioral health, adding a complementary IME capability with an established statewide referral network to the Red Bank-based platform. (Link)
  4. Morgan Stanley/TPG-backed Guardian Dentistry Partners acquires Majority Stake in Select Dental Management. Guardian Dentistry Partners (GDP), a dental partnership organization capitalized by Morgan Stanley Private Credit, TPG Twin Brook and Prudential, agreed to a majority acquisition of Select Dental Management (SDM), adding 38 locations, 130 dentists and 720 team members across eight Northeastern states and Washington, D.C. SDM grew EBITDA 115% between 2022 and 2024 at roughly 20% practice-level margins. The deal, expected to close before the end of Q3 2026, significantly expands GDP’s geographic reach and reinforces its equity-ownership, dentist-partnership model. For its sponsors, the transaction scales a differentiated DPO platform through affiliation rather than transactional roll-up, prioritizing clinician retention and alignment. (Link)
  5. Family Capital Kaltroco acquired school-based mobile dental provider Smile America Partners from private equity firm Beach Point Capital Management. Kaltroco, a family-owned private investment company with offices in Nashville, Zurich and Cape Town, acquired Smile America Partners, the largest U.S. school-based mobile dental program, from seller Beach Point Capital Management. Terms were undisclosed, though the Farmington Hills, Michigan-based DSO generates roughly $20 million EBITDA on about $100 million revenue. Beach Point had bought majority control in January 2023 from Morgan Stanley Capital Partners. Smile America served over 370,000 children across 8,000-plus schools in 20 states in 2025. Kaltroco, which invests family capital with no outside LPs, backs continued expansion of pediatric dental access under existing CEO Steve Higginbotham. (Link)
  6. Hidden Harbor Capital Partners’ portfolio company Inspire Aesthetics partnered with Colorado-based Millard Plastic Surgery. Inspire Aesthetics, the plastic-surgery management services organization backed by lower-middle-market private equity firm Hidden Harbor Capital Partners, formed a strategic partnership with Millard Plastic Surgery, a Denver/Englewood, Colorado provider founded by Dr. John Millard and supported by four plastic surgeons. Terms were undisclosed. The affiliation extends Inspire’s national roll-up of premium aesthetic practices while preserving physician-led clinical decision-making. For Hidden Harbor, adding a well-regarded Colorado platform advances its buy-and-build thesis in high-end plastic surgery, layering operational resources onto a two-decade-old brand. The deal deepens Inspire’s geographic footprint in the Mountain West as sponsors continue consolidating the fragmented medical-aesthetics market. (Link)
  7. Macquarie Asset Management-backed Health Wave Partners acquired Alamar Senior Living from sellers Walton Street and Scarp Ridge Capital Partners. Health Wave Partners, a Chicago-based senior-housing investment platform backed by a strategic partnership with Macquarie Asset Management, acquired Alamar Senior Living, a 134-unit Class A assisted living and memory care community in Wellington, Florida. The seller was a partnership between Walton Street and Scarp Ridge Capital Partners. Terms were undisclosed. Built in 2018 and 96% occupied after a 2025 renovation, Alamar will continue under operator AgeWell Senior Living. The acquisition expands Health Wave’s presence in South Florida’s demographically favorable senior-housing market, reflecting its strategy of pairing high-quality communities with best-in-class operators to capture demand from an aging population. (Link)
  8. Ascension-owned AMSURG, acquired five North Carolina gastroenterology and endoscopy centers to expand its ambulatory surgery platform. AMSURG, one of the largest U.S. ambulatory surgery center operators with more than 250 centers and now part of Ascension following its roughly $3.9 billion take-private, added five North Carolina centers spanning the state’s eastern and central regions. Terms were undisclosed. The acquired centers bring 15 board-certified gastroenterologists and hepatologists offering colonoscopy, endoscopy and capsule imaging. The tuck-in reflects AMSURG’s continued buy-and-build consolidation of physician-aligned GI assets, deepening regional density in a specialty prized for recurring, outpatient procedure volume. The deal underscores how scaled ASC platforms keep absorbing community practices to strengthen payer positioning and geographic coverage. (Link)
  9. Brookdale Senior Living Inc. (NYSE: BKD) acquired the previously managed Brookdale Galleria community in Houston for $23.4 million. Brookdale Senior Living (NYSE: BKD), the largest U.S. senior-living operator with 541 communities, completed the $23.4 million acquisition of the 244-unit Brookdale Galleria independent and assisted living community in Houston’s affluent Galleria district. Management framed the price as a substantial discount to replacement cost, funding the deal with cash on hand and an expanded line of credit rather than equity issuance. With occupancy below Brookdale’s consolidated average, the company plans a repositioning through modest development capex to capture upside that accrues directly to shareholders. The purchase converts a managed asset into owned real estate in a strategically important market. (Link)
  10. Family-owned Family Hospice acquired North Georgia Community Hospice, LLC to complete its northwest Georgia footprint. Family Hospice, a family-owned, locally operated palliative and hospice provider founded in January 2022 and serving 13 locations across Georgia and South Carolina, completed its acquisition of North Georgia Community Hospice, a Dalton-based provider serving northwest Georgia. Terms were undisclosed. Backed by the nonprofit Family Hospice Foundation, the buyer positioned the deal as extending its full continuum of hospice and palliative services—including additional clinical and bereavement resources—into the region. The transaction reflects steady consolidation among community hospice operators pursuing regional density in a market shaped by favorable senior demographics and rising home-based, end-of-life care utilization across the Southeast. (Link)
  11. Physician-led Summit Spine & Joint Centers acquired Southeast Neurology & Pain Management (SNPM), its third acquisition in three years. Summit Spine & Joint Centers, a physician-led minimally invasive spine and interventional pain platform led by founder-CEO Dr. Amit Patel, acquired Southeast Neurology & Pain Management, adding clinics in Thomasville, Georgia and Tallahassee and Panama City, Florida. Terms were undisclosed. The deal—Summit’s third practice acquisition in three years—lifts its network to 55 clinics and 21 ambulatory surgery centers across Georgia, Florida, North Carolina, South Carolina and Tennessee. The acquisition advances Summit’s strategy of partnering with established physician-led pain practices while preserving local clinical leadership, building regional density in interventional pain as demand for minimally invasive treatment grows across the Southeast. (Link)
  12. Tempus AI, Inc. (NASDAQ: TEM) agreed to acquire Personalis, Inc. (Nasdaq: PSNL) for $16.25 per share, an enterprise value of roughly $1.5 billion. o prTempus AI (NASDAQ: TEM) agreed to acquire Personalis (Nasdaq: PSNL) at $16.25 per share—about $1.5 billion enterprise value net of Tempus’ existing stake—a 6% premium to Friday’s close and 28% to the unaffected 30-day VWAP. The primarily all-stock deal uses a floating exchange ratio capped at 0.3356, with Tempus able to elect up to 50% cash. It builds on a November 2023 partnership in which Tempus invested in Personalis and commercializes its ultrasensitive NeXT Personal MRD test. Tempus is buying deeper into the roughly $20 billion molecular residual disease market, integrating tumor-informed cancer monitoring across its AI-enabled precision-oncology platform; closing is expected late 2026 or early 2027. (Link)
  13. BrainsWay Ltd. (NASDAQ/TASE: BWAoY) made a $500,000 minority preferred-equity investment in outpatient behavioral health platform Sound Minds Behavioral. BrainsWay (NASDAQ/TASE: BWAY), a neurostimulation medtech company, took a minority position in Sound Minds Behavioral through a preferred, annually compounding security, deploying $500,000 as part of a strategic equity financing round. The structure mirrors BrainsWay’s playbook of supplying growth capital to expanding interventional-psychiatry providers while retaining focus on its core Deep TMS technology. Sound Minds operates outpatient mental-health clinics across Connecticut, Pennsylvania, New Jersey and New York, offering therapy, medication management, PHP/IOP and interventional psychiatry. For BrainsWay, the minority-stake model expands its distribution reach and aligns a growth-oriented partner with its device platform without diluting its clinical and scientific priorities. (Link)ot
  14. IPG Photonics Corporation (NASDAQ: IPGP) entered a binding offer to acquire Lumibird Medical from Lumibird SA for €300 million plus a €50 million earn-out. IPG Photonics (NASDAQ: IPGP) agreed to acquire Lumibird Medical for €300 million on a cash-free, debt-free basis, plus up to €50 million contingent on 2026–2027 performance, funding the purchase with cash on hand. France-based Lumibird Medical, whose brands include Quantel Medical, Ellex and Optotek Medical, posted FY2025 revenue of €112.2 million and EBITDA of €24.1 million (21.5% margin). IPG expects the high-margin ophthalmology-and-urology laser business to be accretive to gross margin, EBITDA and adjusted EPS in year one, lifting Advanced Solutions to roughly 26% of sales and adding about $1 billion of addressable market to its medical-laser growth platform. (Link)
  15. PE-backed Raintree acquired agentic-AI voice developer Spike Technologies to advance autonomous revenue-cycle management. Raintree, the leading EHR and practice-management platform for rehabilitation and physical-therapy organizations, acquired San Francisco-based Spike Technologies, a developer of agentic AI voice technology founded in 2022. Terms were undisclosed. The acquisition embeds AI voice agents natively into Raintree’s EMR to automate payer calls, claim follow-ups, eligibility, prior authorization and patient outreach—work that consumes front-desk staff amid roughly 13% claim-denial rates. Management framed the deal as a foundational step toward fully autonomous RCM. Strategically, Raintree is betting that native, context-aware automation—rather than bolted-on chatbots—will compress administrative cost and differentiate its platform in a large, labor-intensive workflow market. (Link)
  16. JLL Partners recapitalized life-sciences services firm CAI. JLL Partners, a New York-based middle-market private equity firm focused on healthcare, industrials and business services, closed a recapitalization of CAI, an Indianapolis-based professional services firm providing commissioning, qualification and validation (CQV) and operational-readiness services to life-sciences and mission-critical customers. Terms were undisclosed; the transaction closed July 1. CAI’s 700-plus professionals operate across North America, Europe, Australia and Asia. JLL Partners, which has deployed roughly $9 billion of equity across 61 platform investments since 1988, aims to accelerate CAI’s global expansion, technology investment and service-line growth—another example of a specialist sponsor backing scaled pharma-services platforms serving highly regulated environments. (Link)
  17. Lyric acquired precision payment-accuracy company Concert to expand its Lyric42 healthcare decision-intelligence platform. Lyric, a Philadelphia-based leader in healthcare decision intelligence for payment accuracy, acquired Concert, a precision-health payment-accuracy company whose proprietary technology translates machine-readable clinical policies into real-time claims decisions. Terms were undisclosed. The acquisition builds on a commercial partnership begun in 2023, during which the pair’s shared diagnostics solution grew nearly tenfold. Lyric, which supports roughly 200 million lives and nine of the top ten U.S. health plans, will embed Concert’s policy intelligence into its AI-powered Lyric42 platform. Strategically, the deal shifts payment integrity toward shared, machine-readable policy standards as genetic testing and specialty therapies reshape plan cost management. (Link)
  18. Warburg Pincus acquired Indian pharmaceuticals company Integrace Private Limited from sellers True North and Temasek. Warburg Pincus, the global growth-investing firm, acquired Integrace Private Limited, an India-based orthopedics- and gynecology-focused pharmaceutical formulations company, from exiting investors True North and Temasek in a deal reported at around ₹1,200 crore (terms officially undisclosed). Integrace holds 20-plus brands—including Lizolid, Stiloz, Mifegest and Cytolog—and relationships with over 45,000 healthcare professionals through science-led marketing. Industry veteran Rehan Khan, formerly of MSD and Abbott India, joins as CEO. Warburg Pincus, active in Indian healthcare for three decades, is betting on building a scaled, therapy-focused branded formulations platform via consolidation in women’s health and orthopedics, backed by predictable chronic-care demand. (Link)
  19. Verdane acquired stakes in four Trifork Labs technology businesses—Axoniq, Dawn Health, Frameo and XCI—from publicly listed Trifork Group (Nasdaq Copenhagen: TRIFOR). Verdane, the Oslo-based specialist growth investor, acquired ownership stakes in four Trifork Labs companies—event-sourcing pioneer Axoniq, patient-centric digital-health business Dawn Health, WiFi photo-frame software provider Frameo, and cybersecurity firm XCI—from Trifork Group (Nasdaq Copenhagen: TRIFOR). Investing via its Freya funds, Verdane acquired 52% of the four companies’ combined €43.6 million book value, paying Trifork €22.8 million cash plus uncapped earnouts; three stakes will be co-owned with Trifork while XCI was fully acquired. Verdane will deploy operational advisors across go-to-market, data, finance and talent, with the digital-health asset Dawn Health anchoring the healthcare relevance of this growth-stage portfolio transaction. (Link)
  20. Avathon Capital-backed Summit Professional Education acquired pediatric pelvic-health educator Kids Bowel & Bladder. Summit Professional Education, a Franklin, Tennessee continuing-education provider backed by Avathon Capital, acquired Kids Bowel & Bladder (KBB), the leading U.S. continuing-education organization for pediatric pelvic health, founded by Dawn Sandalcidi. Terms were undisclosed. The deal extends Summit’s already-strong pelvic-health franchise into pediatric specialty care, adding on-demand and live courses plus a Certificate in Pediatric Pelvic Health. Summit—whose portfolio includes Herman & Wallace Pelvic Rehabilitation Institute, PT Final Exam, the National Federation of Personal Trainers and The Knowledge Tree—has educated over 400,000 clinicians. (Link)
  21. Avera Health (Non Profit Health System) acquired physician-owned multispecialty group The Center for Neurosciences, Orthopaedics & Spine (CNOS). Avera Health, a Sioux Falls-based nonprofit health system, acquired The Center for Neurosciences, Orthopaedics & Spine (CNOS), a physician-owned multispecialty group headquartered in Dakota Dunes, South Dakota. Terms were undisclosed. The deal brings more than 100 physicians and advanced-practice providers plus over 350 staff across nine specialties—including orthopedics, neurosurgery, neurology and gastroenterology—and eight clinic locations into Avera, effective January 1, 2027, when the group becomes Avera CNOS. Building on an existing referral relationship across the South Dakota–Iowa–Nebraska Siouxland region, the acquisition reflects continued health-system consolidation of independent specialty groups to strengthen regional care continuity, employed-physician scale and integrated delivery across a tri-state footprint. (Link)
  22. Zoetis Inc. (NYSE: ZTS) agreed to acquire veterinary teleradiology platform VitalRADS. Zoetis (NYSE: ZTS), the world’s largest animal-health company, agreed to acquire VitalRADS, a veterinary teleradiology services platform, building on a partnership the two announced in August 2025. Terms were undisclosed; closing is expected in Q3 2026. VitalRADS provides cloud-based teleradiology, mobile ultrasound, outpatient imaging and cloud image storage, giving practices around-the-clock access to board-certified specialists across 25-plus species with two-hour STAT reads. Folding VitalRADS into its Global Diagnostics portfolio advances Zoetis’ build-out of an end-to-end Virtual Reference Lab with AI-assisted reporting. Strategically, the deal deepens the animal-health leader’s higher-growth diagnostics and imaging franchise, layering recurring specialist services onto its reference-laboratory network. (Link)
  23. Lōkahi Therapeutics completed a strategic business combination with Glucotrack, Inc. (Nasdaq: GCTK), taking control of the public company. Glucotrack (Nasdaq: GCTK) completed a strategic business combination with Lōkahi Therapeutics, a capital-efficient biopharmaceutical platform that acquires and advances overlooked therapeutic assets via its ai² sourcing model. Lōkahi becomes the operating and controlling business, using Glucotrack’s public listing as a capital-efficient platform; upon stockholder approvals and preferred-stock conversion, Lōkahi securityholders will hold roughly 90% of the combined company on a fully diluted basis. A planned private placement is intended to strengthen the capital structure. Glucotrack’s legacy continuous blood glucose monitoring business will operate as a wholly owned subsidiary. The reverse-merger structure gives Lōkahi public-market access to pursue a repeatable, acquisitive pipeline strategy. (Link)
  24. Johnson & Johnson’s (NYSE: JNJ) DePuy Synthes acquired spine-implant maker Expanding Innovations, Inc. DePuy Synthes, the orthopedics business of Johnson & Johnson (NYSE: JNJ), acquired Expanding Innovations, a Mountain View, California commercial-stage medtech company specializing in expandable interbody cage technology for spine surgery. Terms were undisclosed. Expanding Innovations’ non-screw-based X-PAC portfolio—covering TLIF and LLIF expandable cages and a lumbar plate system—will complement DePuy Synthes’ TriALTIS Spine System and integrate into its VELYS enabling-tech platform. The deal strengthens J&J’s position in the fast-growing expandable interbody cage segment of the lumbar-fusion market. Strategically, it deepens the medtech giant’s spine portfolio and innovation pipeline as it competes for surgeon adoption in higher-growth orthopedic categories. (Link)
  25. Eli Lilly and Company (NYSE: LLY) agreed to acquire psychedelics developer AtaiBeckley Inc. (Nasdaq: ATAI) for up to $3.8 billion. Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley (Nasdaq: ATAI), a New York clinical-stage biotech developing psychedelic-based mental-health therapies, for $6.75 per share in cash—about $2.8 billion upfront and a 26% premium—plus contingent value rights worth up to $2.50 per share (roughly $1 billion), for total potential value near $3.8 billion. AtaiBeckley’s lead candidate, BPL-003, is an intranasal 5-MeO-DMT formulation for treatment-resistant depression. Expected to close in Q3 2026 pending stockholder and regulatory approval, the deal extends Lilly’s cash-fueled acquisition spree beyond obesity and diabetes, bolstering its neuroscience pipeline and validating big pharma’s growing conviction in psychedelic medicine. (Link)

Venture Deals and Other

  1. Index Ventures-led (VC-backed) Chai Discovery Raises $400M Series C. Chai Discovery raised a $400 million Series C led by Index Ventures alongside Kleiner Perkins, Sequoia Capital and Dimension, with new investors including Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD and Sapphire Ventures, plus returning backers Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures and General Catalyst. The round values the AI molecular-design company at $3.8 billion. Investors cited Chai’s rapid product velocity and commercial traction—its models are already deployed at large pharmaceutical partners—as the thesis. The capital accelerates development of Chai’s generative models for de novo antibody and molecule design targeting historically “undruggable” biology. (Link)
  2. Oak HC/FT-led (VC-backed) Corner Health Raises $32.5M Seed + Series A. Corner Health raised $32.5 million across Seed and Series A financing, with its Series A led by Oak HC/FT and participation from First Round Capital and Zigg Capital, alongside earlier backers Homebrew, Pathlight Ventures, Wischoff Ventures and Go Global Ventures. Oak HC/FT, a fintech-and-healthcare specialist managing over $7 billion, framed the primary-care shortage as an infrastructure problem its AI-native operating system, Cora, is built to solve. Corner Health equips nurse practitioners to launch independent practices, having scaled to 70-plus provider-owned clinics and 35,000 patient visits. The capital funds team growth, platform development and multi-state expansion of its clinician-ownership model. (Link)
  3. Lux Capital/VC-backed SONATA Launches Doctor-led Preventive-Health Membership. SONATA launched its physician-led, prevention-focused healthcare membership in New York, San Francisco and Los Angeles, backed by Lux Capital, Box Group, Sunflower Capital and operators from companies including Linear and Ramp. Round size was not disclosed. Co-founded by Sagan Schultz (ex-Linear, McKinsey) and David Deng (ex-Ramp, Flatiron Health), the $2,500-a-year membership combines whole-genome sequencing, 140-plus biomarkers, in-home testing and in-house clinical AI with ongoing board-certified physician care. For its venture backers, SONATA represents a bet on AI-enabled, longitudinal preventive care that synthesizes genomics and biomarkers into personalized, physician-directed plans—positioning the company in the fast-growing consumer preventive-health and longevity market. (Link)
  4. Arteria/VC-backed Provect AI Raises $7M. Provect AI, a Palo Alto medical-imaging software company, raised $7 million led by Arteria Capital and ValueStream Ventures, with participation from Newfund Capital and Sand Hill Angels, alongside FDA 510(k) clearance for its platform. The software reconstructs volumetric 3D images from standard 2D C-arm x-ray data without a CT scanner or added hardware, targeting spine and orthopedic image-guided procedures. Investors are backing a capital-light approach to intraoperative 3D imaging that integrates with existing PACS and navigation systems. The proceeds fund commercial expansion, customer deployments and continued product development as Provect commercializes its cleared technology into surgical workflows. (Link)
  5. Game Changers Ventures-led (VC-backed) Cognify Health Raises Seed. Cognify Health raised a seed round led by Game Changers Ventures to build a healthcare platform for youth athletics, starting with concussion care. Round size was undisclosed. Founded and led by Christian Juzang, Cognify connects families with a concussion specialist via telehealth within 24 hours and provides return-to-learn and return-to-play plans, drawing on clinicians tied to organizations including USA Basketball and UCLA BrainSPORT. For its lead investor, the thesis is building the “default healthcare layer” for youth sports—using concussion care as an entry point into a broader, nationwide integrated pediatric-athletics platform addressing an underserved, geographically fragmented care gap. (Link)
  6. Symbiotic Capital (Growth debt) Provides up to $65M to THINK Surgical. THINK Surgical, a Fremont, California orthopedic surgical-robot maker, secured a debt facility from healthcare-credit firm Symbiotic Capital providing up to $65 million of growth capital—an initial $25 million funded tranche, an additional $15 million milestone tranche, and up to $25 million discretionary. Combined with recent investments from existing backers, management expects the facility to fully finance the company to profitability. Proceeds advance the dual-channel commercial strategy for its TMINI Miniature Robotic System, compatible with roughly 70% of total-knee implants. For Symbiotic, the deal reflects private-credit appetite to fund scaled, commercial-stage medtech growth without dilutive equity at a critical inflection. (Link)
  7. Orlando Health Ventures-led (Health-system/VC) 410 Medical Raises $12M. 410 Medical, a Durham, North Carolina critical-care device company, closed an oversubscribed $12 million financing led by Orlando Health Ventures, with participation from Hatteras Venture Partners, Ballad Health, OSF Healthcare, Rex Health Ventures, CU Healthcare Innovations Fund, Sarnova, Catalyst by Wellstar, Tampa General and an undisclosed strategic investor. The heavy health-system investor syndicate reflects clinical conviction in 410’s LifeFlow rapid fluid-and-blood delivery products, used at 500-plus hospitals and EMS agencies. Orlando Health Ventures deepened an existing partnership by leading the round. Proceeds scale commercial operations and support a next-generation LifeFlow infuser planned for 2027. (Link)
  8. Capital Q Ventures (Strategic partnership investment) in Woddle. Woddle, a smart-nursery and infant-monitoring healthcare startup previously backed by Madison-based HealthX Ventures, announced a strategic partnership and investment from Capital Q Ventures, an Orlando, Florida alternative-investment firm spanning venture capital, private credit and private equity. Round size was undisclosed. Woddle builds technology-enabled tools for parents and caregivers, initially focused on the modern nursery. For Capital Q, the investment adds a consumer-health hardware-and-software company to a portfolio that emphasizes hands-on support for growth-stage businesses. The partnership provides Woddle additional capital and strategic backing as it scales its baby-focused product line and builds out its parenting-support platform. (Link)
  9. Insight Partners-led (Growth/VC-backed) TytoCare Raises $25M+ TytoCare closed an oversubscribed growth round exceeding $25 million led by Insight Partners, with participation from HOOP, OliveTree, OrbiMed, Qumra Capital and Qualcomm Ventures, alongside the appointment of Adam Pellegrini as CEO. Insight Partners, which manages over $90 billion, cited institutional conviction in TytoCare’s market position and demand for AI-enabled remote diagnostics. TytoCare, a remote physical-examination company with FDA-cleared devices and AI software-as-a-medical-device algorithms, is repositioning as an AI-first clinical-enablement platform for chronic and complex disease. Proceeds fund its AI algorithm pipeline, deeper payer and health-system partnerships, and go-to-market expansion into cardiometabolic, oncology and post-acute populations. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 13th, 2026

LECO_Weekly-Healthcare-News_7-13-2026Download

Healthcare Weekly News and Deals –July 13th, 2026

  1. American Industrial Partners agreed to acquire Avanos Medical (NYSE: AVNS) in an all-cash take-private valued at approximately $1.272 billion. American Industrial Partners (AIP), an operationally oriented investor with roughly $17.8 billion in assets, is acquiring Avanos Medical (NYSE: AVNS) for $25.00 per share in cash — a ~72% premium to Avanos’s pre-announcement close — valuing the medical-technology company at about $1.272 billion enterprise value. Having cleared regulatory review, the deal is expected to close by late July 2026 following a July 22 stockholder vote. Alpharetta, Georgia-based Avanos, focused on specialty nutrition and pain-management/recovery devices, will become privately held. AIP plans to leverage its operational playbook to support Avanos’s next phase of innovation and commercial execution. (Link)
  2. TCW Steel City (part of PNC Financial Services Group, NYSE: PNC), alongside co-lenders Brightwood, CIFC and CalSTRS, provided a $170 million recapitalization financing to Colorado-based Lone Peak Dental Group. TCW Steel City — the private-credit platform combining PNC Financial Services Group (NYSE: PNC) and TCW Private Credit — served as lead arranger and administrative agent on a $170 million recapitalization of Lone Peak Dental Group, a Dental Partnership Organization operating 75-plus offices across 14 states. The facility bundled a term loan, revolver and delayed-draw term loan structured to bankroll future acquisitions. Brightwood, CIFC and CalSTRS joined as additional lenders. The senior-secured package reflects private-credit appetite for scaled, mission-driven dental platforms pursuing both de novo and affiliation growth, giving Lone Peak flexible capital to expand pediatric dental access across its footprint. (Link)
  3. Surplus Solutions, a portfolio company of private equity firm NMS Capital, acquired Frederick, Maryland-based DCM BioServices to expand its laboratory-automation technical-service capabilities. NMS Capital, a private equity firm managing more than $2.0 billion across business and healthcare services, added to its Surplus Solutions platform with the acquisition of DCM BioServices, a Frederick, Maryland provider of lab-automation maintenance, repair and integration. Terms were undisclosed. The tuck-in extends Surplus Solutions’ equipment-lifecycle-management model into recurring preventive-maintenance contracts — a stream NMS partner David Peterson framed as a natural extension of existing customer relationships. DCM services 3,000-plus instruments across 200-plus labs nationwide, deepening the platform’s technical bench across leading instrument makers and reinforcing NMS’s buy-and-build thesis in life-sciences services. (Link)
  4. Orthopedic & Balance Therapy Specialists, a seven-clinic Northwest Indiana outpatient physical-therapy practice, was sold to an undisclosed national rehabilitation platform. Orthopedic & Balance Therapy Specialists (OBTS), a seven-location outpatient physical-therapy provider founded in 2003 in Northwest Indiana, completed a sale to an unnamed national rehabilitation platform. Both financial terms and the acquiring platform were left undisclosed. The transaction fits the broader private-equity-driven consolidation of outpatient rehab, where scaled platforms continue absorbing founder-owned, multi-clinic practices with strong payer relationships and regional density. OBTS’s shareholders sought a strategic partner to preserve clinical standards and culture while accessing platform resources for continued growth, positioning the practice to expand within its market under larger ownership. (Link)
  5. EQT (Nasdaq Stockholm: EQT), through its EQT X fund, agreed to acquire the Corza Biosurgery/TachoSil business from Corza Medical, which is backed by private equity firm GTCR. EQT (Nasdaq Stockholm: EQT) agreed to acquire Corza Biosurgery — built around TachoSil, a dual-action hemostat-and-sealant surgical patch — from GTCR-backed Corza Medical. Financial terms were undisclosed; closing is expected in Q4 2026. Investing through its EQT X fund, EQT plans to accelerate U.S. commercial and indication expansion, broaden adoption in underpenetrated markets, and build a wider biosurgery platform via add-on M&A. GTCR, which carved out TachoSil in 2021 and combined it with Surgical Specialties, exits the unit. TachoSil is used across cardiovascular, hepatic, neurological and thoracic procedures in more than 50 countries. (Link)
  6. Onto Health, a fertility and longevity platform backed by ARTIS Ventures and Humania, acquired U.S.-based clinical-decision-support company LEVY Health. Onto Health — a physician-led fertility and longevity provider backed by ARTIS Ventures and Humania — acquired LEVY Health, a U.S. clinical-decision-support software company for reproductive medicine. Terms were undisclosed. The purchase follows Onto’s roughly $20 million Series A and provides the technological backbone for a scalable, tech-enabled fertility-care infrastructure spanning the United States and the Gulf Cooperation Council region. LEVY’s diagnostics help clinics identify endocrine disorders and streamline fertility workups, letting practices fold low-complexity fertility care into existing models. The deal signals investor appetite for AI-enabled infrastructure plays in the multi-billion-dollar global fertility-services market. (Link)
  7. ResMed (NYSE: RMD) agreed to sell its MatrixCare software business to private equity firm Frazier Healthcare Partners for $490 million in cash. ResMed (NYSE: RMD) agreed to divest its MatrixCare post-acute-care software unit to Frazier Healthcare Partners, a healthcare-focused private equity firm, in a $490 million all-cash deal expected to close in the first quarter of ResMed’s fiscal 2027. ResMed, which paid $750 million for MatrixCare in 2018, will redeploy proceeds toward shareholder returns via an accelerated share repurchase while sharpening its sleep-and-breathing focus. MatrixCare — serving 15,000-plus skilled-nursing, senior-living and home-health providers — generated roughly $220 million revenue and $55 million adjusted operating profit in fiscal 2026. Frazier, which has raised over $11 billion, gains a scaled long-term-care software platform. (Link)
  8. Steel Partners Holdings (NYSE: SPLP), a shareholder of InMode (NASDAQ: INMD), offered to acquire the medical-aesthetics company for $16.75 per share in cash, topping a competing CEO-led bid. Steel Partners Holdings (NYSE: SPLP), which owns roughly 1.3% of InMode (NASDAQ: INMD), launched an unsolicited $16.75-per-share all-cash offer for the Israeli medical-aesthetics maker — a 20% premium to the $13.95 unaffected price and $0.55 above a rival buyout led by CEO Moshe Mizrahy. Steel argued the CEO’s $16.20 bid undervalued InMode using a low 2026 EBITDA estimate, demanded Mizrahy’s removal over governance conflicts, and urged the board to form an independent committee. Steel also offered existing holders the option to roll up to 40% of their equity into the privatized company, intensifying the contested sale process. (Link)
  9. Emergency Care Partners — backed by private equity firms Varsity Healthcare Partners, MidOcean Partners and Regal Healthcare Capital Partners — partnered with Phoenix-based Empower Emergency Physicians. Emergency Care Partners (ECP), the largest single-specialty emergency-medicine physician-services provider in the U.S. and backed by Varsity Healthcare Partners, MidOcean Partners and Regal Healthcare Capital Partners, formed a strategic partnership with Empower Emergency Physicians, a Phoenix independent group serving Dignity Health’s St. Joseph’s hospitals. Terms were undisclosed. The deal extends Pensacola-based ECP’s Southwest footprint to more than 1.7 million annual patient encounters across ten states while preserving Empower’s physician-led model. It reflects the sponsors’ buy-and-build strategy of consolidating physician-owned groups under ECP’s infrastructure, building on MidOcean’s 2025 preferred-equity investment that funds continued acquisitions. (Link)
  10. Incline Equity Partners acquired a majority stake in medical and health physics testing provider West Physics from LNC Partners, which retains a minority interest. Incline Equity Partners acquired a majority equity interest in Atlanta-based West Physics, a provider of medical and health physics testing and consulting that certifies MRI, CT and X-ray equipment against ACR, IAC and Joint Commission standards across 6,000-plus client sites in all 50 states and abroad. Terms were undisclosed. Seller LNC Partners — which first invested in May 2018 and grew revenue more than 3.7x over seven years through organic expansion and six add-on acquisitions — rolls over a minority position alongside Incline. Founder-CEO Dr. Geoffrey West continues to lead, with both sponsors backing further organic growth and M&A into adjacent services and geographies. (Link)
  11. Cygnet Group, backed by parent company Universal Health Services (NYSE: UHS), acquired Orchard Care Group in the Republic of Ireland. Cygnet Group — the UK mental-health and social-care provider owned by Universal Health Services (NYSE: UHS) — acquired Orchard Care Group, an integrated fostering, residential and disability-care provider in the Republic of Ireland. Terms were undisclosed. Orchard operates 39 residential and community homes plus two day services and employs over 550 people, with its executive team staying on. The deal marks Cygnet’s first residential-support expansion beyond the UK, extending UHS’s international social-care reach. It follows Cygnet’s recent run of UK acquisitions and hospital builds, signaling continued consolidation of specialist care assets under the publicly traded U.S. hospital operator. (Link)
  12. HCC Healthcare signed a business-combination agreement with SPAC RF Acquisition Corp III (Nasdaq: RFAM) to pursue a Nasdaq listing at a roughly $500 million equity value. Singapore-incorporated HCC Healthcare, which runs integrated medical and long-term-care services through Taiwan subsidiaries, agreed to merge with RF Acquisition Corp III (Nasdaq: RFAM), a publicly traded special-purpose acquisition company, to go public on Nasdaq. The deal reflects a pre-transaction equity value of approximately $500 million at $10.00 per share, with closing targeted for Q4 2026 subject to shareholder and regulatory approvals. On a pro forma basis, the combined Taiwan-focused network spans 120-plus long-term-care facilities and 9,000-plus beds. The SPAC route gives HCC public-market capital to scale its aging-population care model across Taiwan, Japan and Asia. (Link)
  13. Austin, Texas-based private equity firm CenterGate Capital invested in Canadian Dental Labs (CDL), Canada’s leading manufacturer of dental prosthetics and orthodontic appliances. CenterGate Capital, an Austin, Texas private equity firm, made a control investment in Canadian Dental Labs (CDL), the Toronto-headquartered platform that is Canada’s leading maker of dental prosthetics and orthodontic appliances. Terms were undisclosed. CDL — comprising labs including Shaw Lab Group, Protec Dental and Hallmark — serves 5,000-plus dental professionals and DSOs nationwide, with CEO Ali Rezaei continuing to lead. CenterGate backs the platform’s next growth phase, funding investment in people, technology and its coast-to-coast laboratory network. The deal underscores private equity’s appetite for scaled, technology-forward dental-lab consolidators with recurring, patient-specific manufacturing demand. (Link)
  14. ReFocus Eye Health, the management-services organization backed by Zenyth Partners, partnered with Connecticut’s 11-location Solinsky EyeCare. ReFocus Eye Health — a Northeast ophthalmology management-services organization backed by investment firm Zenyth Partners — affiliated with Solinsky EyeCare, an 11-location comprehensive ophthalmology and optometry practice serving Greater Hartford, Connecticut. Terms were undisclosed. Adding Solinsky’s 14 ophthalmologists and optometrists lifts ReFocus’s network to more than 250 affiliated physicians across 114 locations in nine states. The affiliation preserves physicians’ clinical autonomy while providing operational and administrative support, reflecting Zenyth-backed ReFocus’s continued regional roll-up strategy. The transaction adds to a wave of private-equity-sponsored consolidation in eye care as platforms pursue density in attractive Northeastern markets. (Link)
  15. CONMED Corporation (NYSE: CNMD) is weighing a potential sale after receiving takeover interest from unnamed private equity firms. CONMED Corporation (NYSE: CNMD), a surgical-device maker focused on orthopedic and general surgery, saw shares jump as much as 10% after Bloomberg reported the company is exploring strategic options following acquisition interest from private equity firms. No formal sale process has been confirmed and specific bidders have not been disclosed. CONMED, whose products include sports-medicine implants, electrosurgery systems and the AirSeal platform, has been sharpening its focus on higher-margin surgical segments after exiting gastroenterology lines. The reported interest highlights sustained private-equity appetite for scaled medtech assets, though any transaction remains speculative pending confirmation of a formal review. (Link)
  16. Clarivate Plc (NYSE: CLVT) agreed to sell its Life Sciences & Healthcare segment to healthcare-focused investment firm Altaris LLC for $600 million. Clarivate Plc (NYSE: CLVT) agreed to divest its Life Sciences & Healthcare segment to Altaris LLC, an investment firm focused exclusively on healthcare, for $600 million. Clarivate receives $500 million cash at closing plus $25 million deferred, using proceeds to cut debt and sharpen its subscription-first focus on Academia & Government and Intellectual Property. The company expects a $225–250 million non-cash goodwill impairment. For Altaris, the carve-out delivers a data-and-analytics platform supporting decision-making across the drug and device lifecycle. The transaction reflects the recurring theme of publicly traded information providers shedding non-core units to specialist private-equity buyers. (Link)
  17. Private equity firm Warburg Pincus, partnering with the Abu Dhabi Investment Authority, is nearing a $7 billion-plus acquisition of specialty pharmacy PANTHERx Rare from owners General Atlantic, Nautic Partners and The Vistria Group. Warburg Pincus, which manages over $100 billion, is in advanced talks to acquire Pittsburgh-based specialty pharmacy PANTHERx Rare for more than $7 billion including debt, partnering with sovereign-wealth fund the Abu Dhabi Investment Authority. PANTHERx, focused on rare and orphan-disease medicines and patient support, is owned by a consortium of General Atlantic, Nautic Partners and The Vistria Group, which bought it from Centene in 2022. Nothing is finalized and timing could slip. The deal reflects private equity’s bet on recession-resistant, high-margin orphan-drug demand and the growing pattern of buyout firms pairing with sovereign-wealth capital on large checks. (Link)
  18. Halma plc (LSE: HLMA) acquired Summit Partners-backed Dreampath Diagnostics for an initial €154 million plus an earn-out of up to €121 million. UK-listed Halma plc (LSE: HLMA) acquired Dreampath Diagnostics, a Strasbourg-based provider of automated tissue-sample management systems for pathology labs, from growth-equity firm Summit Partners. Halma is paying an initial €154 million (about $132 million) in cash, with a performance-based earn-out of up to €121 million through 2028. Summit, which made an undisclosed growth investment in 2025, exits after helping Dreampath scale to 300-plus million samples across 500-plus labs in 50 countries. Dreampath — forecasting roughly €33 million revenue for the year to March 2027 — will run standalone within Halma’s Healthcare Sector, strengthening its diagnostics traceability capabilities. (Link)
  19. Spero Health — backed by Heritage Group, Health Velocity Capital, South Central Inc. and Frist Cressey Ventures — acquired CleanSlate Centers, backed by Granite Growth Health Partners, HealthQuest Capital and CRG. Spero Health, a Nashville-area outpatient addiction-treatment provider owned by Heritage Group, Health Velocity Capital, South Central Inc. and Frist Cressey Ventures, acquired multi-state opioid-treatment operator CleanSlate Centers — backed by Granite Growth Health Partners, HealthQuest Capital and CRG — in a deal that closed July 1 and averts CleanSlate’s shutdown. Spero assumed CleanSlate’s equity interests in exchange for taking on its debt and deal costs; terms were undisclosed. The combination roughly doubles Spero’s footprint to 128 locations across ten states, with heavy overlap in Ohio, Indiana and Kentucky, reflecting Spero’s thesis that consolidation strengthens payer leverage. (Link)
  20. Private equity firm Enhanced Healthcare Partners made a growth investment in LeadingReach, healthcare’s largest connected referral network. Enhanced Healthcare Partners (EHP), a healthcare-focused private equity firm, made a growth investment in Austin-based LeadingReach, operator of healthcare’s largest verified referral network spanning 30,000-plus organizations, 60,000-plus care settings and 125,000-plus providers processing 25,000 daily referrals. Terms were undisclosed. EHP adds experienced healthcare operators to LeadingReach’s board and provides resources to accelerate AI-powered automation, deeper EHR integrations and expanded network infrastructure following the company’s recent acquisition of iNaira Healthcare Technologies. The investment reflects EHP’s focus on founder-led health-IT platforms positioned to benefit from the industry’s shift toward value-based care and referral coordination. (Link)
  21. Shore Capital Partners, a healthcare-focused private equity firm, acquired Denver-based employee-benefits technology platform ThrivePass. Shore Capital Partners, a Chicago-based private equity firm with roughly $17 billion in assets, acquired ThrivePass, a Denver employee-benefits administration technology platform founded by Wade Rosen, Andreas Deptolla and Charles Shen. Terms were undisclosed. The investment funds continued development of ThrivePass’s configurable platform — spanning lifestyle spending accounts, rewards, tuition reimbursement, COBRA and pre-tax benefits for employers, brokers and PEOs. Shore brings healthcare-focused operational resources and a consolidation playbook to scale the business as demand grows for digital-first benefits tools. The deal extends Shore’s health-tech portfolio, targeting a lower-middle-market platform with organic and acquisition-driven growth potential. (Link)
  22. Integrity, LLC acquired Stride Health, the portable-benefits technology platform powering gig-economy insurance enrollment for partners including Uber, DoorDash and Amazon Flex. Dallas-based insurance distributor Integrity, LLC acquired Stride Health, a San Francisco portable-benefits technology platform that helps independent and gig workers enroll in health, dental, vision and life coverage. Terms were undisclosed. Stride — founded in 2014 and previously Allstate-backed — connects 4.6 million-plus workers and 140-plus enterprise partners including Uber, DoorDash, Gusto and Amazon Flex. Integrity folds Stride’s consumer marketplace into its IntegrityCONNECT agent platform and roughly 600,000-strong agent network, expanding into the under-65 individual market where tens of millions lack employer coverage. The deal pairs digital enrollment with agent-assisted distribution as worker-misclassification rules reshape portable-benefits demand. (Link)
  23. Principal Financial Group (Nasdaq: PFG) agreed to acquire digitally-native ancillary employee-benefits company Beam Benefits to expand its small-business protection platform. Principal Financial Group (Nasdaq: PFG) agreed to acquire Beam Benefits, a cloud-native ancillary employee-benefits company serving over 25,000 small businesses with dental, vision, life, disability and supplemental health coverage. Terms were undisclosed. Beam — built on an AI-powered underwriting and self-service technology stack and available in 46 states plus D.C. — generated roughly $175 million in premiums in 2025. Principal, which serves 180,000 employers, expects the deal to close in the latter half of 2026 and to lift Specialty Benefits premium and fee growth to at or above the high end of its 5–9% medium-term target in 2027. The digital-first model adds scalable capabilities to Principal’s SMB strategy. (Link)

Venture Deals and Other

  1. Valspring Capital led a $28 million Series B in Pediatrica Health Group, with participation from existing investor M33 Growth. Pediatrica Health Group, a Miami-based multi-site pediatric primary-care organization, closed a $28 million Series B led by Boston growth-equity firm Valspring Capital, with existing backer M33 Growth participating. The capital funds organic growth and strategic acquisitions plus investment in clinical infrastructure, technology and value-based-care capabilities. Pediatrica — founded through its partnership with M33 — has scaled to 21 locations across Florida and Texas. Valspring, formed by Bain Capital Ventures’ former healthcare team, cited its thesis that lasting healthcare change comes from companies innovating on patient and provider experience. The round backs continued expansion of equitable pediatric primary-care access. (Link)
  2. RPS Ventures led a $19 million Series B in Handspring Health, with new investor Angelini Ventures joining returning backers Cobalt Ventures, NextView Ventures, nvp capital, Hyde Park Angels and Cornucopian Capital. Handspring Health, a virtual youth mental-health provider, raised a $19 million Series B led by RPS Ventures, with new investor Angelini Ventures joining returning backers Cobalt Ventures, NextView Ventures, nvp capital, Hyde Park Angels and Cornucopian Capital. The round — lifting total funding to $37 million — funds clinician hiring, deeper value-based-care partnerships with payers, broader geographic reach and technology investment. Handspring, which employs rather than contracts its therapists and trains them in-house in evidence-based modalities, has treated 4,000-plus patients across nine states and grown revenue more than tenfold in two years. RPS’s Nancy Hilliker joins the board. (Link)
  3. Surface Ventures led a $3 million seed round in Octozi, with participation from Remarkable Ventures and following a prior investment from Debiopharm’s venture arm. Octozi, a New York agentic-AI company automating clinical-trial data operations for pharmaceutical sponsors, raised $3 million in seed funding led by Surface Ventures, with Remarkable Ventures participating and building on an earlier stake from Swiss pharma Debiopharm’s venture arm. The capital expands Octozi’s human-in-the-loop platform, which integrates with clinical systems to automate data cleaning, reconciliation, review and reporting. A peer-reviewed study found the tool boosted data-cleaning throughput roughly sixfold and cut reviewer error rates from about 55% to 8%, with estimated savings above $5 million per Phase III oncology trial. Surface Ventures’ Gyan Kapur framed the bet on compressing drug-development timelines. (Link)
  4. Andreessen Horowitz led a $50 million equity round for Pearl Health, joined by Viking Global Investors, AlleyCorp and Ulysses Capital, alongside a $60 million debt facility led by Trinity Capital (NASDAQ: TRIN). Pearl Health, a New York health-technology company enabling providers to manage risk for Medicare patients, raised $110 million — a $50 million equity round led by Andreessen Horowitz with Viking Global Investors, AlleyCorp and Ulysses Capital, plus a $60 million debt facility led by Trinity Capital (NASDAQ: TRIN). The capital funds AI-platform expansion, new risk products, Medicare Advantage entry and enterprise health-system and payer partnerships. Pearl — profitable in 2025 — supports 10,000-plus providers across 40-plus states serving 250,000-plus beneficiaries and manages roughly $3.6 billion in annualized medical spend. a16z’s Vineeta Agarwala praised Pearl’s technology-led approach to value-based payment. (Link)